


```

* PRIOR FILING DATE: 1999-08-25
; PRIOR APPLICATION NUMBER: US 60/141,037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: US 60/092,182
; PRIOR FILING DATE: 1998-07-09
; NUMBER OF SEQ ID NOS: 532
; SEQ ID NO 376
; LENGTH: 713
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-219-538-376

Query Match      100.0%; Score 713; DB 1; Length 713;
Best Local Similarity 100.0%; Pred. No. 3.4;
Matches 713; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AATATATCATCTATTATCAATTAATCAATATGTAATCTTTTATTCCTCAATCAATTTGGG 60
DB 1 AATATATCATCTATTATCAATTAATCAATATGTAATCTTTTATTCCTCAATCAATTTGGG 60
QY 61 TTTTGGGATTTTAAATTTCAACACAGCAGAGATGACATTTTCTGTCTCACTATTATTT 120
DB 61 TTTTGGGATTTTAAATTTCAACACAGCAGAGATGACATTTTCTGTCTCACTATTATTT 120
QY 121 GTTGATGTGAAGCTATTGAGATCCCAATTCAGGAAGCAACACATTTGGAGATGGCTA 180
DB 121 GTTGATGTGAAGCTATTGAGATCCCAATTCAGGAAGCAACACATTTGGAGATGGCTA 180
QY 181 CTCTTCTATCAAGAATAAAGAGAACCAACAGTCAACCCACAGCAAGGCTAGTTAAGGACG 240
DB 181 CTCTTCTATCAAGAATAAAGAGAACCAACAGTCAACCCACAGCAAGGCTAGTTAAGGACG 240
QY 241 TGTGACTCTACCAAGCTGTCAAAACCAACAGGCAAGGCTAGTTAAGGACGGAATCT 300
DB 241 TGTGACTCTACCAAGCTGTCAAAACCAACAGGCAAGGCTAGTTAAGGACGGAATCT 300
QY 301 TGACTCAAGAGGGTTAAATCTTTGGTGTGAAGCTGTGAAGCTGTGAAGCTGTGAAGCT 360
DB 301 TGACTCAAGAGGGTTAAATCTTTGGTGTGAAGCTGTGAAGCTGTGAAGCTGTGAAGCT 360
QY 361 TTAGATTCATGAATGTAATTTAAATTTAAATTTAAATTTAAATTTAAATTTAAATTTAA 420
DB 361 TTAGATTCATGAATGTAATTTAAATTTAAATTTAAATTTAAATTTAAATTTAAATTTAA 420
QY 421 GTATCCCTGTCAATATATATATATATATATATATATATATATATATATATATATATAT 480
DB 421 GTATCCCTGTCAATATATATATATATATATATATATATATATATATATATATATATAT 480
QY 481 AGTTCTAAATTTGGAGCTTTTAAATTTTAAATTTTAAATTTTAAATTTTAAATTTTAAAT 540
DB 481 AGTTCTAAATTTGGAGCTTTTAAATTTTAAATTTTAAATTTTAAATTTTAAATTTTAAAT 540
QY 541 GCTTAGATCTACAGGAGATCATATAATTTGATACAAATAAAGAAAGAGTGTCTCTCCCC 600
DB 541 GCTTAGATCTACAGGAGATCATATAATTTGATACAAATAAAGAAAGAGTGTCTCTCCCC 600
QY 601 TTACAGAATTTGACATTTTAAATTTGCGATACAGTTAGAAATAGGAAATATGACATTAGA 660
DB 601 TTACAGAATTTGACATTTTAAATTTGCGATACAGTTAGAAATAGGAAATATGACATTAGA 660
QY 661 AAGAATGACAGGAGAAAGAAAGAGGAAATGTTGCCAAGGAAAAA 713
DB 661 AAGAATGACAGGAGAAAGAAAGAGGAAATGTTGCCAAGGAAAAA 713

```

```

RESULT 506
US-10-147-528-473
; Sequence 473, Application US/10147528
; Publication No. US20030219885A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura

```

```

; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C334
; CURRENT APPLICATION NUMBER: US/10/147,528
; CURRENT FILING DATE: 2002-05-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 473
; LENGTH: 713
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-528-473

Query Match      100.0%; Score 713; DB 1; Length 713;
Best Local Similarity 100.0%; Pred. No. 3.4;
Matches 713; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AATATATCATCTATTATCAATTAATCAATATGTAATCTTTTATTCCTCAATCAATTTGGG 60
DB 1 AATATATCATCTATTATCAATTAATCAATATGTAATCTTTTATTCCTCAATCAATTTGGG 60
QY 61 TTTTGGGATTTTAAATTTTCAACACAGCAGAGATGACATTTTCTGTCTCACTATTATTT 120
DB 61 TTTTGGGATTTTAAATTTTCAACACAGCAGAGATGACATTTTCTGTCTCACTATTATTT 120
QY 121 GTTGATGTGAAGCTATTGAGATCCCAATTCAGGAAGCAACACATTTGGAGATGGCTA 180
DB 121 GTTGATGTGAAGCTATTGAGATCCCAATTCAGGAAGCAACACATTTGGAGATGGCTA 180
QY 181 CTCTTCTATCAAGAATAAAGAGAACCAACAGTCAACCCACAGCAAGGCTAGTTAAGGACG 240
DB 181 CTCTTCTATCAAGAATAAAGAGAACCAACAGTCAACCCACAGCAAGGCTAGTTAAGGACG 240
QY 241 TGTGACTCTACCAAGCTGTCAAAACCAACAGGCAAGGCTAGTTAAGGACGGAATCT 300
DB 241 TGTGACTCTACCAAGCTGTCAAAACCAACAGGCAAGGCTAGTTAAGGACGGAATCT 300
QY 301 TGACTCAAGAGGGTTAAATCTTTGGTGTGAAGCTGTGAAGCTGTGAAGCTGTGAAGCT 360
DB 301 TGACTCAAGAGGGTTAAATCTTTGGTGTGAAGCTGTGAAGCTGTGAAGCTGTGAAGCT 360
QY 361 TTAGATTCATGAATGTAATTTAAATTTAAATTTAAATTTAAATTTAAATTTAAATTTAA 420
DB 361 TTAGATTCATGAATGTAATTTAAATTTAAATTTAAATTTAAATTTAAATTTAAATTTAA 420
QY 421 GTATCCCTGTCAATATATATATATATATATATATATATATATATATATATATATATAT 480
DB 421 GTATCCCTGTCAATATATATATATATATATATATATATATATATATATATATATATAT 480
QY 481 AGTTCTAAATTTGGAGCTTTTAAATTTTAAATTTTAAATTTTAAATTTTAAATTTTAAAT 540
DB 481 AGTTCTAAATTTGGAGCTTTTAAATTTTAAATTTTAAATTTTAAATTTTAAATTTTAAAT 540
QY 541 GCTTAGATCTACAGGAGATCATATAATTTGATACAAATAAAGAAAGAGTGTCTCTCCCC 600
DB 541 GCTTAGATCTACAGGAGATCATATAATTTGATACAAATAAAGAAAGAGTGTCTCTCCCC 600
QY 601 TTACAGAATTTGACATTTTAAATTTGCGATACAGTTAGAAATAGGAAATATGACATTAGA 660
DB 601 TTACAGAATTTGACATTTTAAATTTGCGATACAGTTAGAAATAGGAAATATGACATTAGA 660

```

Db 601 TTACAGAAATGACATTTTAAATCGATACAGTTAGTAATAGGAATATGACATTAGAAAGG 660
 QY 661 AAGAAATGACAGGAGAAAGGAAAGGAAATGTTGCCAAGGAAAAA 713
 Db 661 AAGAAATGACAGGAGAAAGGAAAGGAAATGTTGCCAAGGAAAAA 713

RESULT 507

US-10-128-692A-473
 ; Sequence 473, Application US/10128692A
 ; Publication No. US20040009547A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: P3330R1C124
 ; CURRENT APPLICATION NUMBER: US/10/128,692A
 ; CURRENT FILING DATE: 2002-10-15
 ; PRIOR APPLICATION NUMBER: 60/049911
 ; PRIOR FILING DATE: 1997-06-18
 ; PRIOR APPLICATION NUMBER: 60/056974
 ; PRIOR FILING DATE: 1997-08-26
 ; PRIOR APPLICATION NUMBER: 60/059113
 ; PRIOR FILING DATE: 1997-09-17
 ; PRIOR APPLICATION NUMBER: 60/059115
 ; PRIOR FILING DATE: 1997-09-17
 ; PRIOR APPLICATION NUMBER: 60/059117
 ; PRIOR FILING DATE: 1997-09-17
 ; PRIOR APPLICATION NUMBER: 60/059122
 ; PRIOR FILING DATE: 1997-09-17
 ; PRIOR APPLICATION NUMBER: 60/059184
 ; PRIOR FILING DATE: 1997-09-17
 ; PRIOR APPLICATION NUMBER: 60/059263
 ; PRIOR FILING DATE: 1997-09-18
 ; PRIOR APPLICATION NUMBER: 60/059352
 ; PRIOR FILING DATE: 1997-09-19
 ; PRIOR APPLICATION NUMBER: 60/059588
 ; PRIOR FILING DATE: 1997-09-19
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 473
 ; LENGTH: 713
 ; TYPE: DNA
 ; ORGANISM: Homo Sapien
 US-10-128-692A-473

Query Match 100.0%; Score 713; DB 1; Length 713;
 Best Local Similarity 100.0%; Pred. No. 3.4;
 Matches 713; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AATATATCATCTATTATCATTAATCAATATGATTTTATTTTCCATATACATTGGG 60
 Db 1 AATATATCATCTATTATCATTAATCAATATGATTTTATTTTCCATATACATTGGG 60
 QY 61 TTTTGGGATTTTAAATTTCAACACAGCAGATGACATTTTCTGCTACTATTATT 120
 Db 61 TTTTGGGATTTTAAATTTCAACACAGCAGATGACATTTTCTGCTACTATTATT 120

QY 121 GTTGTATGTGAAGCTATTTGGAGATCCAAATTCAGGAAGCAACACATTTGGAGATGGCTA 180
 Db 121 GTTGTATGTGAAGCTATTTGGAGATCCAAATTCAGGAAGCAACACATTTGGAGATGGCTA 180
 QY 181 CTTTCTATCAAGAAATAAAGAGAACCAAGTCACACCCCAACAATCATCTTTAGAGACAG 240
 Db 181 CTTTCTATCAAGAAATAAAGAGAACCAAGTCACACCCCAACAATCATCTTTAGAGACAG 240
 QY 241 TGTGACTCTTACCAAGCTGTCAAAACCAAGGCAAGGCGATAGTTAAAGGCGGAATCT 300
 Db 241 TGTGACTCTTACCAAGCTGTCAAAACCAAGGCAAGGCGATAGTTAAAGGCGGAATCT 300
 QY 301 TGACTCAAGAGGGTTAAATTTCTTGTGTCTGAAGCCCTGGGGCAGGGGTGTAAGAAAAACAC 360
 Db 301 TGACTCAAGAGGGTTAAATTTCTTGTGTCTGAAGCCCTGGGGCAGGGGTGTAAGAAAAACAC 360
 QY 361 TTAGATTCATGATTTGTAATTTAAAGGCAATACACATATTAGTATTACCTTAGTGTAA 420
 Db 361 TTAGATTCATGATTTGTAATTTAAAGGCAATACACATATTAGTATTACCTTAGTGTAA 420
 QY 421 GTATCCCTGTCTATATACAAATAGGTGAAATTAAGTACCTATGAGTTGGCTGGAC 480
 Db 421 GTATCCCTGTCTATATACAAATAGGTGAAATTAAGTACCTATGAGTTGGCTGGAC 480
 QY 481 AGTTCTAAATTTGGACTTTTAAATTTTAAATCACTAATCACTGATTTATCACTGGCTATGT 540
 Db 481 AGTTCTAAATTTGGACTTTTAAATTTTAAATCACTAATCACTGATTTATCACTGGCTATGT 540
 QY 541 GCTTAGATCTACAGAGATCATATAATTTGATACAAATAAAGAAAGTGTCTCTCCCC 600
 Db 541 GCTTAGATCTACAGAGATCATATAATTTGATACAAATAAAGAAAGTGTCTCTCCCC 600
 QY 601 TTACAGAAATGCATTTTAAATGCGATACAGTTAGGAATATGACATTAGAAAGG 660
 Db 601 TTACAGAAATGCATTTTAAATGCGATACAGTTAGGAATATGACATTAGAAAGG 660
 QY 661 AAGAAATGACAGGAGAAAGGAAAGGAAATTTGCCAAGGAAAAA 713
 Db 661 AAGAAATGACAGGAGAAAGGAAAGGAAATTTGCCAAGGAAAAA 713

RESULT 508

US-10-140-927-473
 ; Sequence 473, Application US/10140927
 ; Publication No. US20040009548A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: P3330R1C180
 ; CURRENT APPLICATION NUMBER: US/10/140,927
 ; CURRENT FILING DATE: 2002-05-07
 ; Prior Application removed - See File Wrapper or Palm
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 473
 ; LENGTH: 713

```
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-927-473

Query Match      100.0%; Score 713; DB 1; Length 713;
Best Local Similarity 100.0%; Pred. No. 3.4;
Matches 713; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AATATATCATCTATTTATCATTAATCAATAATGATTTCTTTTATTCCTCAATAAATTTGGG 60
Db 1 AATATATCATCTATTTATCATTAATCAATAATGATTTCTTTTATTCCTCAATAAATTTGGG 60
QY 61 TTTTGGGATTTTAAATTTTCAACACAGCAGAAATGACATTTTCTGTCACTATTATTATT 120
Db 61 TTTTGGGATTTTAAATTTTCAACACAGCAGAAATGACATTTTCTGTCACTATTATTATT 120
QY 121 GTTGGTATGTGAAGCTATTTGGAGATCCAAATCAGGAAGCAACACATTTGGAGATGGCTA 180
Db 121 GTTGGTATGTGAAGCTATTTGGAGATCCAAATCAGGAAGCAACACATTTGGAGATGGCTA 180
QY 181 CTTTCTATCAAGAAATAAAGAGAACCAAGTCAACCCACACATCAATCATCTTTAGAGACAG 240
Db 181 CTTTCTATCAAGAAATAAAGAGAACCAAGTCAACCCACACATCAATCATCTTTAGAGACAG 240
QY 241 TGTGACTCTCAACCAAGCTGTCAAAAACACAGGCAAGGCGATAGTTAAAGACGGAATCT 300
Db 241 TGTGACTCTCAACCAAGCTGTCAAAAACACAGGCAAGGCGATAGTTAAAGACGGAATCT 300
QY 301 TGAAGTCAAGAGGGTTAAATTTCTGTGCTGAAGCTGGGGCAGGGGTGTAAAGAAAACAC 360
Db 301 TGAAGTCAAGAGGGTTAAATTTCTGTGCTGAAGCTGGGGCAGGGGTGTAAAGAAAACAC 360
QY 361 TTAGATTCATGATTTGAAATTTAAAGCAAAATACACATATTAGTATTACCTTAGTGTAAAT 420
Db 361 TTAGATTCATGATTTGAAATTTAAAGCAAAATACACATATTAGTATTACCTTAGTGTAAAT 420
QY 421 GTATCCCTGTCAATATACAAATAGGTGAAATTAATTAAGTACCTTACGAGTTGGCTGGAC 480
Db 421 GTATCCCTGTCAATATACAAATAGGTGAAATTAATTAAGTACCTTACGAGTTGGCTGGAC 480
QY 481 AGTTCTAAATTTGGACTTTTAAATTTTAAATCAGTAACTGATTTATCACTGGCTATGT 540
Db 481 AGTTCTAAATTTGGACTTTTAAATTTTAAATCAGTAACTGATTTATCACTGGCTATGT 540
QY 541 GCATTAGATCTACAGGAGATCATATAATTTGATACAAATAAAGAAAAGTGTCTCTCCCC 600
Db 541 GCATTAGATCTACAGGAGATCATATAATTTGATACAAATAAAGAAAAGTGTCTCTCCCC 600
QY 541 GCATTAGATCTACAGGAGATCATATAATTTGATACAAATAAAGAAAAGTGTCTCTCCCC 600
Db 541 GCATTAGATCTACAGGAGATCATATAATTTGATACAAATAAAGAAAAGTGTCTCTCCCC 600
QY 601 TTACAGAAATTTGACATTTTAAATTCGATACAGTGTAGAAATAGGAATATGACATTAGAAAG 660
Db 601 TTACAGAAATTTGACATTTTAAATTCGATACAGTGTAGAAATAGGAATATGACATTAGAAAG 660
QY 661 AAGAAATGACAGGGAGAAAGGAAAGGAAAGTGTGCCAAGGAAAAA 713
Db 661 AAGAAATGACAGGGAGAAAGGAAAGGAAAGTGTGCCAAGGAAAAA 713
```

RESULT 509

```
US-10-147-536-473
; Sequence 473, Application US/10147536
; Publication No. US20040077064A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
```

```
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C349
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 473
; LENGTH: 713
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-536-473

Query Match      100.0%; Score 713; DB 1; Length 713;
Best Local Similarity 100.0%; Pred. No. 3.4;
Matches 713; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AATATATCATCTATTTATCATTAATCAATAATGATTTCTTTTATTCCTCAATAAATTTGGG 60
Db 1 AATATATCATCTATTTATCATTAATCAATAATGATTTCTTTTATTCCTCAATAAATTTGGG 60
QY 61 TTTTGGGATTTTAAATTTTCAACACAGCAGAAATGACATTTTCTGTCACTATTATTATT 120
Db 61 TTTTGGGATTTTAAATTTTCAACACAGCAGAAATGACATTTTCTGTCACTATTATTATT 120
QY 121 GTTGGTATGTGAAGCTATTTGGAGATCCAAATCAGGAAGCAACACATTTGGAGATGGCTA 180
Db 121 GTTGGTATGTGAAGCTATTTGGAGATCCAAATCAGGAAGCAACACATTTGGAGATGGCTA 180
QY 181 CTTTCTATCAAGAAATAAAGAGAACCAAGTCAACCCACACATCAATCATCTTTAGAGACAG 240
Db 181 CTTTCTATCAAGAAATAAAGAGAACCAAGTCAACCCACACATCAATCATCTTTAGAGACAG 240
QY 241 TGTGACTCTCAACCAAGCTGTCAAAAACACAGGCAAGGCGATAGTTAAAGACGGAATCT 300
Db 241 TGTGACTCTCAACCAAGCTGTCAAAAACACAGGCAAGGCGATAGTTAAAGACGGAATCT 300
QY 301 TGAAGTCAAGAGGGTTAAATTTCTGTGCTGAAGCTGGGGCAGGGGTGTAAAGAAAACAC 360
Db 301 TGAAGTCAAGAGGGTTAAATTTCTGTGCTGAAGCTGGGGCAGGGGTGTAAAGAAAACAC 360
QY 361 TTAGATTCATGATTTGAAATTTAAAGCAAAATACACATATTAGTATTACCTTAGTGTAAAT 420
Db 361 TTAGATTCATGATTTGAAATTTAAAGCAAAATACACATATTAGTATTACCTTAGTGTAAAT 420
QY 421 GTATCCCTGTCAATATACAAATAGGTGAAATTAATTAAGTACCTTACGAGTTGGCTGGAC 480
Db 421 GTATCCCTGTCAATATACAAATAGGTGAAATTAATTAAGTACCTTACGAGTTGGCTGGAC 480
QY 481 AGTTCTAAATTTGGACTTTTAAATTTTAAATCAGTAACTGATTTATCACTGGCTATGT 540
Db 481 AGTTCTAAATTTGGACTTTTAAATTTTAAATCAGTAACTGATTTATCACTGGCTATGT 540
QY 541 GCATTAGATCTACAGGAGATCATATAATTTGATACAAATAAAGAAAAGTGTCTCTCCCC 600
Db 541 GCATTAGATCTACAGGAGATCATATAATTTGATACAAATAAAGAAAAGTGTCTCTCCCC 600
QY 601 TTACAGAAATTTGACATTTTAAATTCGATACAGTGTAGAAATAGGAATATGACATTAGAAAG 660
Db 601 TTACAGAAATTTGACATTTTAAATTCGATACAGTGTAGAAATAGGAATATGACATTAGAAAG 660
QY 661 AAGAAATGACAGGGAGAAAGGAAAGGAAAGTGTGCCAAGGAAAAA 713
Db 661 AAGAAATGACAGGGAGAAAGGAAAGGAAAGTGTGCCAAGGAAAAA 713
```

RESULT 510

US-10-270-470-5
; Sequence 5, Application US/10270470
; Publication No. US20030162955A1
; GENERAL INFORMATION:
; APPLICANT: Chalus, Lionel
; APPLICANT: Quan, Ahn B.
; APPLICANT: Bates, Elizabeth Ester Mary
; APPLICANT: Gorman, Daniel M.
; APPLICANT: Saeland, Sem
; APPLICANT: Lebecque, Serge J.E.
; APPLICANT: Phillips, Joseph H.
; TITLE OF INVENTION: ISOLATED MAMMALIAN MEMBRANE PROTEIN GENES; RELATED REAGENTS
; FILE REFERENCE: DX0802QK
; CURRENT APPLICATION NUMBER: US/10/270,470
; CURRENT FILING DATE: 1999-03-16
; PRIOR APPLICATION NUMBER: US 09/270,368
; PRIOR FILING DATE: 1999-03-16
; PRIOR APPLICATION NUMBER: US 60/078,334
; PRIOR FILING DATE: 1998-03-17
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
; LENGTH: 1018
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (160)..(900)
; OTHER INFORMATION:
US-10-270-470-5

Query Match 19.6%; Score 140; DB 1; Length 1018;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 140; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 134 GCTATTGGAGATCCAATTTCAGGAAGCAACACATTGGAGAAATGGCTACTTTCTATCAAGA 193
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
361 GCTATTGGAGATCCAATTTCAGGAAGCAACACATTGGAGAAATGGCTACTTTCTATCAAGA 420
QY 194 AATAAGAGAACACAGTCAACCCACACATCATCTTTAGAGACAGTGTGACTCTCTACC 253
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
421 AATAAGAGAACACAGTCAACCCACACATCATCTTTAGAGACAGTGTGACTCTCTACC 480
QY 254 AAAGCTGTCAAAACACAGG 273
Db ||||||||||||||||||||
481 AAAGCTGTCAAAACACAGG 500

Search completed: June 2, 2004, 16:49:49
Job time : 184 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2004, 16:18:53 ; Search time 227 Seconds
(without alignments)
3.966 Million cell updates/sec

Title: US-09-989-293A-376

Perfect score: 713

Sequence: 1 aatatcatcatctatttatca.....tggccaaggagaaaaaaa 713

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 8 seqs, 631314 residues

Total number of hits satisfying chosen parameters: 16

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 8 summaries

Database : rge376.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB	ID	Description
1	713	100.0	713	1	AR252626	ACCESSION:AR252626
2	713	100.0	713	1	AX055452	ACCESSION:AX055452
3	713	100.0	713	1	AX403489	ACCESSION:AX403489
4	713	100.0	713	1	AX464340	ACCESSION:AX464340
5	713	100.0	713	1	AY358685	ACCESSION:AY358685
C 6	705.6	99.0	165414	1	AC024224	ACCESSION:AC024224
C 7	594.7	83.4	240864	1	AC006510	ACCESSION:AC006510
C 8	211.499	29.7	221471	1	AC138620	ACCESSION:AC138620

ALIGNMENTS

RESULT 1
AR252626
LOCUS AR252626 713 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 376 from patent US 6478825.
ACCESSION AR252626
VERSION AR252626.1 GI:27300534

KEYWORDS Unknown.

SOURCE Unclassified.

ORGANISM 1 (bases 1 to 713)

REFERENCE Winterbottom J.M., Shimp L., Boyce T.M. and Kaes D.

AUTHORS Implant, method of making same and use of the implant for the

TITLE treatment of bone defects

JOURNAL Patent: US 6478825-A 376 12-NOV-2002;

FEATURES Location/Qualifiers

1..713

/organism="unknown"

/mol_type="genomic DNA"

Query Match 100.0%; Score 713; DB 1; Length 713;
Best Local Similarity 100.0%; Pred. No. 4.7;
Matches 713; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 AATATATCATCTATTATTCATTAATCAATATATGTAATCTTTTATTCCTTATTCCTAATAAATTTGGG 60
DB 1 AATATATCATCTATTATTCATTAATCAATATATGTAATCTTTTATTCCTAATAAATTTGGG 60
QY 61 TTTTGGGATTTTAAATTTTCAAACACAGCAGATGACATTTTTCGTCTCACTATTATTATT 120
DB 61 TTTTGGGATTTTAAATTTTCAAACACAGCAGATGACATTTTTCGTCTCACTATTATTATT 120
QY 121 GTTGTATGTGAAGCTATTGTGAGATCCAATTCAGGAAGCAACACATTGGGAATGGCTA 180
DB 121 GTTGTATGTGAAGCTATTGTGAGATCCAATTCAGGAAGCAACACATTGGGAATGGCTA 180
QY 181 CTTTCTATCAAGAAATAAAGAGAACACAGTCAACCCACACATCATCTTTAGAGACAG 240
DB 181 CTTTCTATCAAGAAATAAAGAGAACACAGTCAACCCACACATCATCTTTAGAGACAG 240
QY 241 TGTGACTCTTACCAAGCTGTCAAACACACAGGCAAGGCATAGTTAAAGGACGGAATCT 300
DB 241 TGTGACTCTTACCAAGCTGTCAAACACACAGGCAAGGCATAGTTAAAGGACGGAATCT 300
QY 301 TGACTCAAGAGGGTTAAATTTCTTGGTCTGAAGCCTGGGGCAGGGGTGTAAGAAACAC 360
DB 301 TGACTCAAGAGGGTTAAATTTCTTGGTCTGAAGCCTGGGGCAGGGGTGTAAGAAACAC 360
QY 361 TTAGATTCAATGATTGTAAATTTTAGGCAATATACATATTTAGTATTAATCTTAGTGTAA 420
DB 361 TTAGATTCAATGATTGTAAATTTTAGGCAATATATACATATTTAGTATTAATCTTAGTGTAA 420
QY 421 GTATCCCTGTCTATATACAAATAGGTGAAATTTAAGTACCCCTATGCAAGTTGGCTGGAC 480
DB 421 GTATCCCTGTCTATATACAAATAGGTGAAATTTAAGTACCCCTATGCAAGTTGGCTGGAC 480
QY 481 AGTTCTAAATTTGGACTTTTAAATTTTAAATTCAGTAACTGATTTATCCTGGCTATGT 540
DB 481 AGTTCTAAATTTGGACTTTTAAATTTTAAATTCAGTAACTGATTTATCCTGGCTATGT 540
QY 541 GCTTAGATCTACAGGAGATCATATAATTTGATACAAATAAAGAAAGTCTCTCCCC 600
DB 541 GCTTAGATCTACAGGAGATCATATAATTTGATACAAATAAAGAAAGTCTCTCCCC 600
QY 601 TTACAGAAATTCATTTTAAATTCGATACAGTTAGAAATAGGAATATGACATTAGAAAG 660
DB 601 TTACAGAAATTCATTTTAAATTCGATACAGTTAGAAATAGGAATATGACATTAGAAAG 660
QY 661 AAGATGACAGGAGAGAAAGGAAAGGAAATGTTGCCAAGGAAAAA 713
DB 661 AAGATGACAGGAGAGAAAGGAAAGGAAATGTTGCCAAGGAAAAA 713
```

RESULT 2
AX055452

LOCUS AX055452

DEFINITION Sequence 82 from Patent WO0073452.

ACCESSION AX055452

VERSION AX055452.1 GI:12228719

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1

AUTHORS Ashkenazi, A.J., Baker, K.P., Chan, B., Goddard, A., Godowski, P.J.,

Gurney, A.L., Hebert, C., Hensel, W., Kabakoff, R.C., Shelton, D.L.,

Tuma, D., Watanabe, C.K. and Wood, W.I.

TITLE Compositions and methods for the treatment of immune related

diseases

JOURNAL Patent: WO 0073452-A 82 07-DEC-2000;

Genentech, Inc. (US)

FEATURES Location/Qualifiers

```
source
1. .713
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 100.0%; Score 713; DB 1; Length 713;
Best Local Similarity 100.0%; Pred. No. 4.7;
Matches 713; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AATATATCATCTATTATTCATTAATCAATATGATTTCTTTTATCCAAATACATTTGGG 60
Db 1 AATATATCATCTATTATTCATTAATCAATATGATTTCTTTTATCCAAATACATTTGGG 60
Qy 61 TTTTGGGATTTAAATTTTCAACACAGCAGAAATGACATTTTCTGTCTACATTTATT 120
Db 61 TTTTGGGATTTAAATTTTCAACACAGCAGAAATGACATTTTCTGTCTACATTTATT 120
Qy 121 GTTGGTATGTAAGCTATTTTGGAGATCCAAATTCAGGAGCAACACATTTGGAGATGCTA 180
Db 121 GTTGGTATGTAAGCTATTTTGGAGATCCAAATTCAGGAGCAACACATTTGGAGATGCTA 180
Qy 181 CTTTCTATCAAGAAATAAAGAGAACACACAGTCACACCCACACAAATCATCTTTAGAGACAG 240
Db 181 CTTTCTATCAAGAAATAAAGAGAACACACAGTCACACCCACACAAATCATCTTTAGAGACAG 240
Qy 241 TGTGACTCCTACCAAGCTGTCAAAACACAGGCAAGGCGATAGTTAAAGGACGGAATCT 300
Db 241 TGTGACTCCTACCAAGCTGTCAAAACACAGGCAAGGCGATAGTTAAAGGACGGAATCT 300
Qy 301 TGACTCAAGGGTAAATTTCTGTGCTGAAGCTGGGCGAGGGTGTAAAGAAAACAC 360
Db 301 TGACTCAAGGGTAAATTTCTGTGCTGAAGCTGGGCGAGGGTGTAAAGAAAACAC 360
Qy 361 TTAGATTCATAGTGTAAATTTAAGGCAATACACATATTAGTATTACCTTAGTGTAA 420
Db 361 TTAGATTCATAGTGTAAATTTAAGGCAATACACATATTAGTATTACCTTAGTGTAA 420
Qy 421 GTATCCCTGTCAATATACAAATAAGGTGAAATTAATAGTACCCTATGCGCTGGAC 480
Db 421 GTATCCCTGTCAATATACAAATAAGGTGAAATTAATAGTACCCTATGCGCTGGAC 480
Qy 481 AGTTCTAAATTTGGACTTTTAAATTTTAAATCAGTAACCTGATTTACCTGGCTATGT 540
Db 481 AGTTCTAAATTTGGACTTTTAAATTTTAAATCAGTAACCTGATTTACCTGGCTATGT 540
Qy 541 GCTTAGATCTACAGGAGATCATATAATTTGATACAAATAAAGAAAGTGTCTCTCCC 600
Db 541 GCTTAGATCTACAGGAGATCATATAATTTGATACAAATAAAGAAAGTGTCTCTCCC 600
Qy 601 TTACAGAAATGACATTTTAAATGCGATACAGTTAGAAATAGAAATATGACATTAGAAGG 660
Db 601 TTACAGAAATGACATTTTAAATGCGATACAGTTAGAAATAGAAATATGACATTAGAAGG 660
Qy 661 AAGAATGACAGGAGAAAGGAAAGGAAAGTGTGCCAAGGAAAAA 713
Db 661 AAGAATGACAGGAGAAAGGAAAGGAAAGTGTGCCAAGGAAAAA 713

RESULT 3
AX403489 713 bp DNA linear PAT 14-JUN-2002
LOCUS AX403489
DEFINITION Sequence 376 from Patent WO0073454.
ACCESSION AX403489
VERSION AX403489.1 GI:21436980
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
Ashkenazi,A.J., Baker,K.P., Botstein,D., Desnovers,L., Eaton,D.,
Ferrara,N., Gerber,H., Gerritsen,M., Goddard,A., Godowski,P.,
Grimaldi,C.J., Gurney,A.L., Kljavin,I., Napier,M.A., Pan,J.,
Paoni,N.F., ROY,M., Stewart,T.A., Tumas,D., Watanabe,C.K.,
Williams,P., Wood,W.I. and Zhang,Z.
Secreted and transmembrane polypeptides and nucleic acids encoding
the same
Patent: WO 0073454-A 376 07-DEC-2000;
Genentech Inc. (US)
Location/Qualifiers
1. .713
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

TITLE
JOURNAL
Patent: WO 0073454-A 376 07-DEC-2000;
Genentech Inc. (US)
Location/Qualifiers
1. .713
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

FEATURES
source
1. .713
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 100.0%; Score 713; DB 1; Length 713;
Best Local Similarity 100.0%; Pred. No. 4.7;
Matches 713; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AATATATCATCTATTATTCATTAATCAATATGATTTCTTTTATCCAAATACATTTGGG 60
Db 1 AATATATCATCTATTATTCATTAATCAATATGATTTCTTTTATCCAAATACATTTGGG 60
Qy 61 TTTTGGGATTTAAATTTTCAACACAGCAGAAATGACATTTTCTGTCTACATTTATT 120
Db 61 TTTTGGGATTTAAATTTTCAACACAGCAGAAATGACATTTTCTGTCTACATTTATT 120
Qy 121 GTTGGTATGTAAGCTATTTTGGAGATCCAAATTCAGGAGCAACACATTTGGAGATGCTA 180
Db 121 GTTGGTATGTAAGCTATTTTGGAGATCCAAATTCAGGAGCAACACATTTGGAGATGCTA 180
Qy 181 CTTTCTATCAAGAAATAAAGAGAACACACAGTCACACCCACACAAATCATCTTTAGAGACAG 240
Db 181 CTTTCTATCAAGAAATAAAGAGAACACACAGTCACACCCACACAAATCATCTTTAGAGACAG 240
Qy 241 TGTGACTCCTACCAAGCTGTCAAAACACAGGCAAGGCGATAGTTAAAGGACGGAATCT 300
Db 241 TGTGACTCCTACCAAGCTGTCAAAACACAGGCAAGGCGATAGTTAAAGGACGGAATCT 300
Qy 301 TGACTCAAGGGTAAATTTCTGTGCTGAAGCTGGGCGAGGGTGTAAAGAAAACAC 360
Db 301 TGACTCAAGGGTAAATTTCTGTGCTGAAGCTGGGCGAGGGTGTAAAGAAAACAC 360
Qy 361 TTAGATTCATAGTGTAAATTTAAGGCAATACACATATTAGTATTACCTTAGTGTAA 420
Db 361 TTAGATTCATAGTGTAAATTTAAGGCAATACACATATTAGTATTACCTTAGTGTAA 420
Qy 421 GTATCCCTGTCAATATACAAATAAGGTGAAATTAATAGTACCCTATGCGCTGGAC 480
Db 421 GTATCCCTGTCAATATACAAATAAGGTGAAATTAATAGTACCCTATGCGCTGGAC 480
Qy 481 AGTTCTAAATTTGGACTTTTAAATTTTAAATCAGTAACCTGATTTACCTGGCTATGT 540
Db 481 AGTTCTAAATTTGGACTTTTAAATTTTAAATCAGTAACCTGATTTACCTGGCTATGT 540
Qy 541 GCTTAGATCTACAGGAGATCATATAATTTGATACAAATAAAGAAAGTGTCTCTCCC 600
Db 541 GCTTAGATCTACAGGAGATCATATAATTTGATACAAATAAAGAAAGTGTCTCTCCC 600
Qy 601 TTACAGAAATGACATTTTAAATGCGATACAGTTAGAAATAGAAATATGACATTAGAAGG 660
Db 601 TTACAGAAATGACATTTTAAATGCGATACAGTTAGAAATAGAAATATGACATTAGAAGG 660
Qy 661 AAGAATGACAGGAGAAAGGAAAGGAAAGTGTGCCAAGGAAAAA 713
Db 661 AAGAATGACAGGAGAAAGGAAAGGAAAGTGTGCCAAGGAAAAA 713

RESULT 4
AX464340 713 bp DNA linear PAT 16-JUL-2002
LOCUS AX464340
DEFINITION Sequence 473 from Patent WO0140466.
ACCESSION AX464340
VERSION AX464340.1 GI:21899186
KEYWORDS Homo sapiens (human)
SOURCE
```



```

Db      301  TGACTCAAGAGGGTTAAATCTTGCTGCTGAAGCTGGGGCAGGGGCTGTAAAGAAAAACAC 360
Qy      361  TTAGATTCAATGATTGTAATTTAAGGCAATATACATATATAGTATTACCTTAGTGTAAAT 420
Db      361  TTAGATTCAATGATTGTAATTTAAGGCAATATACATATATAGTATTACCTTAGTGTAAAT 420
Qy      421  GTATCCCTGTCATATATACATATAGGTTGAAATTATAAGTACCCTATGCGATTGGCTGGAC 480
Db      421  GTATCCCTGTCATATATACATATAGGTTGAAATTATAAGTACCCTATGCGATTGGCTGGAC 480
Qy      481  AGTTCTAAATGGACTTTATTAATTTTAAATCAGTAACTGATTATCACTGCTATGT 540
Db      481  AGTTCTAAATGGACTTTATTAATTTTAAATCAGTAACTGATTATCACTGCTATGT 540
Qy      541  GCTTAGATCTACAGGAGTATATTAATTTGATACAAATAAAGAAAGTGTCTCTCCCC 600
Db      541  GCTTAGATCTACAGGAGTATATTAATTTGATACAAATAAAGAAAGTGTCTCTCCCC 600
Qy      601  TTACAGAAATTGACATTTTAAATGCGATACAGTTAGATAGGAAATATGACATTAGAAGG 660
Db      601  TTACAGAAATTGACATTTTAAATGCGATACAGTTAGATAGGAAATATGACATTAGAAGG 660
Qy      661  AAGAAATGACGGGAGAAAGAAAGAAAGTGTGCGCAAGGAAAAAAA 713
Db      661  AAGAAATGACGGGAGAAAGAAAGAAAGTGTGCGCAAGGAAAAAAA 713

```

```

RESULT 6
AC024224/c
LOCUS   AC024224.33 GI:21240476
DEFINITION Homo sapiens 12 BAC RP11-1331i4 (Roswell Park Cancer Institute Human BAC Library) complete sequence.
ACCESSION AC024224
VERSION   AC024224.33
KEYWORDS  HTG.
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
REFERENCE 1 (bases 1 to 165414)
AUTHORS   Muzny,D.M., Adams,C., Adio-Oduola,B., Ali-osman,F.R., Allen,C., Alsbrooks,S.L., Amarantunge,H.C., Are,J.R., Ayele,M., Banks,T., Barbara,J., Benton,J., Bimaga,K., Blankenburg,K., Bonnin,D., Bouck,J., Bowie,S., Brivaga,M., Brown,E., Brown,M., Bryant,N.P., Buhay,C., Burch,P., Burchett,C., Burrell,K.L., Byrd,N.C., Carron,T.F., Carter,M., Cavazos,S.R., Chacko,J., Chavez,D., Chen,G., Chen,R., Chen,Z., Chiu,D., Chowdhry,I., Christopoulos,C., Cleveland,C.D., Cox,C., Coyie,M.D., Dathorne,S.R., David,R., Davila,M.B., Davis,C., Davy-Carroll,L., Dederich,D.A., Delaney,K.R., Delgado,O., Denn,A.L., Ding,Y., Dinh,H.H., Douthwaite,K.J., Draper,H., Dugan-Rocha,S., Durbin,K.J., Earhart,C., Edgar,D., Edwards,C.C., Elhaj,C., Emerling,S., Escotto,M., Falls,T., Ferraguto,D., Flagg,N., Ford,J., Foster,P., Frantz,P., Gabisi,A., Gao,J., Garcia,A., Garner,T., Garza,N., Gill,R., Gorrell,J.H., Guevara,W., Gunaratne,P., Hale,S., Hamilton,K., Han,J., Harris,C., Harris,K., Hart,M., Havlik,P., Hawes,A., Hernandez,J., Hernandez,O., Hodgson,A., Hogues,M., Holloway,C., Hollins,B., Homs,F., Howard,S., Huber,J., Hulyk,S., Hume,J., Ioshikhes,I., Jackson,L.E., Jacobson,B., Jia,Y., Johnson,R., Jolivet,S., Joudah,S., Karlsson,E., Kelly,S., Khan,U., King,L., Korvah,J., Kovar,C., Kratovic,J., Kureshi,A., Landry,N., Leal,B., Lee,B., Lewis,L.C., Lewis,L., Li,J., Li,Z., Lichtarge,O., Liu,C., Liu,J., Liu,W., Louleghed,H., Lozado,R.J., Lu,X., Lucier,A., Lucier,R., Luna,R., Ma,J., Maheshwari,M., Mapua,P., Marondel,I., Martin,R., Martindale,A., Martinez,E., Massey,B., Mashiney,E., McLeod,M.P., Meador,M., Mei,G., Merscher,S., Metzker,M., Miller,A., Miner,G., Miner,Z., Mitchell,T., Mohabbat,K., Montgomery,K.T., Morgan,M., Morris,S., Moser,M., Neal,D., Nelson,D., Newton,J., Newton,N., Nguyen,A., Nguyen,N., Nguyen,N., Nickerson,E., Nwokenkwo,S., Ogih,M., Okwuonu,G., Oragunye,N., Oviedo,R., Pace,A., Payton,B., Peary,J., Perez,L., Peters,L., Pickens,R., Primus,E., Pu,L.L., Quiles,M., Ren,Y., Rives,W., Rojas,A., Rojubokan,I., Rolfe,M., Ruiz,S., Savery,G.,

```

```

TITLE    Scherer,S., Scott,G., Shen,H., Shim,C., Shooshitari,N., Sisson,I.,
JOURNAL   Sodergren,E., Sonaike,T., Sparks,A., Stanley,H., Stone,H.,
AUTHORS   Sutton,A., Svatek,A., Tabor,P., Tamerisa,A., Tamerisa,K., Tang,H.,
AUTHORS   Tansey,J., Taylor,C., Taylor,T., Telford,B., Thomas,N., Thomas,S.,
AUTHORS   Usmani,K., Vazquez,L., Vera,V., Villalobos,D., Vinson,R., Wang,Q.,
AUTHORS   Wang,S., Ward-Moore,S., Warren,R., Washington,C., Watlington,S.,
AUTHORS   Williams,G., Williamson,A., Wleczyk,R., Wooden,S., Worley,K.,
AUTHORS   Wu,C., Wu,Y., Wu,Y.F., Zhou,J., Zorrilla,S., Kucherlapati,R.,
AUTHORS   Weinstein,G. and Gibbs,R.
TITLE     Direct Submission
JOURNAL   Unpublished
AUTHORS   2 (bases 1 to 165414)
AUTHORS   Worley,K.C.
TITLE     Direct Submission
JOURNAL   Submitted (28-FEB-2000) Human Genome Sequencing Center, Department
AUTHORS   of Molecular and Human Genetics, Baylor College of Medicine, One
AUTHORS   Baylor Plaza, Houston, TX 77030, USA
TITLE     3 (bases 1 to 165414)
AUTHORS   Worley,K.C.
TITLE     Direct Submission
JOURNAL   Submitted (26-MAY-2002) Human Genome Sequencing Center, Department
AUTHORS   of Molecular and Human Genetics, Baylor College of Medicine, One
AUTHORS   Baylor Plaza, Houston, TX 77030, USA
TITLE     4 (bases 1 to 165414)
AUTHORS   Worley,K.C.
TITLE     Direct Submission
JOURNAL   Submitted (29-MAY-2002) Human Genome Sequencing Center, Department
AUTHORS   of Molecular and Human Genetics, Baylor College of Medicine, One
AUTHORS   Baylor Plaza, Houston, TX 77030, USA
TITLE     On May 29, 2002 this sequence version replaced gi:21206012.
AUTHORS   INFORMATION: http://www.hgsc.bcm.tmc.edu/ or email
AUTHORS   gc-help@bcm.tmc.edu

```

CLONE LENGTH: This sequence does not necessarily represent the entire insert of this clone. Overlapping regions of clones are only sequenced and submitted once, so the sequence for the remainder of the insert may be found in the record for the adjacent clones. Overlapping clones are noted at the beginning and end of the Features listing.

ANNOTATION OF FEATURES:

STSs are identified using ePCR (Genome Res. 7:541-550) searches of a local database that includes entries from dbSTS, GDB, and local mapping efforts.

Repeats are identified using RepeatMasker (A. Smit and P. Green, unpublished.) for Human and Mouse sequences.

Genes and Region of sequence similarity are identified by BLAST (Nuc. Acids Res. 25:3389-3402) similarity (expect < 1e-34) to the EST and cDNA sequences. Genes demonstrate at least two exons flanked by consensus splice sites that maintained sequence continuity across the splice junctions. Sequences that are not identical matches are annotated as similar.

SEQUENCING READ COVERAGE: Sequencing is completed to a minimum standard of double strand coverage with a minimum of 2 clones and 2 reads with no ambiguities or 2 chemistries with a minimum of 2 clones and 3 reads with no ambiguities. If the sequence quality for a region does not meet this standard, it will be indicated in the annotation as Low Coverage.

QUALITY OF INDIVIDUAL BASES: This sequence meets stringent quality standards - estimated error rate less than 1 per 10,000 bases. Reports of lowest quality individual bases and measures of base quality are listed below. Description of the metrics can be found at URL:

http://gc.bcm.tmc.edu:8088/quality.info/genbank.annotation.html.

QUALSTAT REPORT.

```

Location/Qualifiers
1. 165414
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

```

FEATURES

source

```
/chromosome="12"
/clone="RP11-133L14"
/complement(482..533)
/rpt_family="MLT1D"
717..777
/rpt_family="(TC)n"
754..774
/notes="Variable size of homopolymeric repeat in subclones"
/function="unresolved homopolymeric run"
778..814
/rpt_family="(CA)n"
/complement(2040..2134)
/rpt_family="MIR"
/complement(2987..3137)
/rpt_family="L1PA3"
/complement(4558..4629)
/rpt_family="MERSA"
4859..4941
/rpt_family="AT_rich"
6420..6491
/rpt_family="Charlie2"
/complement(6577..6703)
/rpt_family="MIR"
6766..6966
/rpt_family="Charlie2"
6980..7102
/rpt_family="Charlie2"
7137..7184
/rpt_family="AT_rich"
/complement(7215..7505)
/rpt_family="L1NA4"
8877..8904
/rpt_family="AT_rich"
/complement(9745..10034)
/rpt_family="AluJb"
11418..11839
/rpt_family="MSTA"
11849..12009
/rpt_family="MER5B"
/complement(12307..12483)
/rpt_family="MER5B"
12963..13065
/rpt_family="CT-rich"
13089..13114
/rpt_family="AT_rich"
/complement(13288..13579)
/rpt_family="MLT1A1"
/complement(13580..13891)
/rpt_family="AluJo"
/complement(13892..13987)
/rpt_family="MLT1A1"
15398..15421
/rpt_family="AT_rich"
/complement(15682..16231)
/rpt_family="L1NA10"
16224..16401
/rpt_family="L1NA10"
16811..17275
/rpt_family="L1PA8"
17310..17655
/rpt_family="THB1B"
18054..18101
/rpt_family="MIR"
18102..18318
/rpt_family="CT-rich"
19226..19319
/rpt_family="MIR"
19743..19811
/rpt_family="L1M2"
19816..19837
/rpt_family="(TC)n"
19837..19882
/rpt_family="(TA)n"
```

```
repeat_region complement(20182..20549)
repeat_region /rpt_family="L1MC2"
20550..21060
/rpt_family="MER9"
repeat_region complement(21061..21138)
repeat_region /rpt_family="L1MC2"
complement(21141..21268)
/rpt_family="MER52C"
22220..22301
/rpt_family="AluJ/FLAM"

Query Match 99.0%; Score 705.6; DB 1; Length 165414;
Best Local Similarity 99.4%; Pred. No. 0.022;
Matches 708; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 AATATATCATCTATTATCAATTAATCAATTAATGTTATCTTTTATCCCAATACATTGGG 60
Db 117419 AATATATCATCTATTATCAATTAATCAATTAATGTTATCTTTTATCCCAATACATTGGG 117360
QY 61 TTTTGGGATTTAAATTTCAAACACACAGCAGATGACATTTTCTGTCACTATTATT 120
Db 117359 TTTTGGGATTTAAATTTCAAACACACAGCAGATGACATTTTCTGTCACTATTATT 117300
QY 121 GTTGTATCTGAAGCTATTGAGATCCAAATTCAGGAAGCAACACATTCGGAATCGCTA 180
Db 117299 GTTGTATCTGAAGCTATTGAGATCCAAATTCAGGAAGCAACACATTCGGAATCGCTA 117240
QY 181 CTTTCTATCAAGAAATAAAGAGAACACACAGTCAACCCACACATCATCTTTAGAACAG 240
Db 117239 CTTTCTATCAAGAAATAAAGAGAACACACAGTCAACCCACACATCATCTTTAGAACAG 117180
QY 241 TGTGACTCTCAAAAGCTGTCAAACACACAGCAGGCGCATAGTTAAAGGACGGAATCT 300
Db 117179 TGTGACTCTCAAAAGCTGTCAAACACACAGCAGGCGCATAGTTAAAGGACGGAATCT 117120
QY 301 TGACTCAAGAGGGTTAAATCTTGGTGCTGAAGCCTGGGGCAGGGGTGTAAAGAAAACAC 360
Db 117119 TGACTCAAGAGGGTTAAATCTTGGTGCTGAAGCCTGGGGCAGGGGTGTAAAGAAAACAC 117060
QY 361 TTAGATTCAATGATGTTAAATTTAAGGCAAAATACACATATTAGTATTACTTAGTCTAAT 420
Db 117059 TTAGATTCAATGATGTTAAATTTAAGGCAAAATACACATATTAGTATTACTTAGTCTAAT 117000
QY 421 GTATCCCTGTCATATATACAAATAAGTGAAATTAAGTACCCTATGCAGTTGGCTGGAC 480
Db 116999 GTATCCCTGTCATATATACAAATAAGTGAAATTAAGTACCCTATGCAGTTGGCTGGAC 116940
QY 481 AGTTCTAAATTCGACCTTTATTAATTTTAAATCAGTAACGTATTTATCACTGGCTATGT 540
Db 116939 AGTTCTAAATTCGACCTTTATTAATTTTAAATCAGTAACGTATTTATCACTGGCTATGT 116880
QY 541 GCTTAGATCTACAGGAGATCATATATTTGATACAAATAAAGAAAAGTGTCTCTCCCC 600
Db 116879 GCTTAGATCTACAGGAGATCATATATTTGATACAAATAAAGAAAAGTGTCTCTCCCC 116820
QY 601 TTACAGAAATTCAGATTTAAATTCGGATACAGTTAGAAATAGGAAATATGACATTAGAAAG 660
Db 116819 TTACAGAAATTCAGATTTAAATTCGGATACAGTTAGAAATAGGAAATATGACATTAGAAAG 116760
QY 661 AGAATGACAGGAGAAAGAAAGGAAATGTTGCCAAGGAAAAAAA 712
Db 116759 AAGAATGACAGGAGAAAGAAAGGAAATGTTGCCAAGGAAATGTTGCCAAGGAAATAGGAA 116708

RESULT 7
AC006510/c
LOCUS Homo sapiens clone RP11-133L13, RP11-656E20, *** SEQUENCING IN
DEFINITION PROGRESS ***, 16 unordered pieces.
ACCESSION AC006510
VERSION AC006510.8 GI:10122018
KEYWORDS HTG; HTGS_PHASE1.
SOURCE Homo sapiens (human)
```



```
Db 211451 GAATCTTGACTCAAAGAGGGTTAAATCTTGTTGCTGAAGCCTGGGCGAGGTGTAAGA 211392
QY 354 AAAACACATTAGATTCATGATGTAATTAATTAAGGCAAAATACACATATTAGTATTACCTTA 413
Db 211391 AAAACACATTAGATTCATGATGTAATTAATTAAGGCAAAATACACATATTAGTATTACCTTA 211332
QY 414 GTGTAATGATCCCTGTCATATATACAAATAAGGTGAATTAATTAAGTACCTATGCAAGTTG 473
Db 211331 GTGTAATGATCCCTGTCATATATACAAATAAGGTGAATTAATTAAGTACCTATGCAAGTTG 211272
QY 474 GGTGGACAGTTCTAAATTCGACTTTATTAATTTTAAATTCAGTAAGTACCTATGCAAGTTG 533
Db 211271 GGTGGACAGTTCTAAATTCGACTTTATTAATTTTAAATTCAGTAAGTACCTATGCAAGTTG 211212
QY 534 GGTATGCTGTAGATTCATGAGGATCATATATTTTATTAATTAAGTACCTATGCAAGTTG 593
Db 211211 GGTATGCTGTAGATTCATGAGGATCATATATTTTATTAATTAAGTACCTATGCAAGTTG 211152
QY 594 TCT--CCCCTTACAGAAATGACATTTTAAATTCGATACAGTTAGAAATGCAATATGACA 651
Db 211151 TCTCGCCCTTACAGAAATGACATTTTAAATTCGATACAGTTAGAAATGCAATATGACA 211092
QY 652 TTAGAAAGGAAGATGACAGGGAAGAAAGGAAGGAAGAAATGTTGCCAAGGAAA 708
Db 211091 TTAGAAAGGAAGATGACAGGGAAGAAAGGAAGGAAGAAATGTTGCCAAGGAAA 211035

RESULT 8
AC138620/c
LOCUS
DEFINITION Mus musculus chromosome UNK clone RP23-250E1, WORKING DRAFT
ACCESSION AC138620
VERSION AC138620.2 GI:28557995
KEYWORDS HTG; HTGS_PHASE1; HTGS_DRAFT; HTGS_FULLTOP.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 221471)
AUTHORS McPherson,J.D. and Waterston,R.H.
TITLE The sequence of Mus musculus clone
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 221471)
AUTHORS McPherson,J.D. and Waterston,R.H.
TITLE Direct Submission
JOURNAL Submitted (12-JAN-2003) Genome Sequencing Center, 4444 Forest Park
Parkway, St. Louis, MO 63108, USA
REFERENCE 3 (bases 1 to 221471)
AUTHORS McPherson,J.D. and Waterston,R.H.
TITLE Direct Submission
JOURNAL Submitted (25-FEB-2003) Genome Sequencing Center, 4444 Forest Park
Parkway, St. Louis, MO 63108, USA
COMMENT On Feb 25, 2003 this sequence version replaced gi:27657609.

----- Genome Center -----
Center: Washington University Genome Sequencing Center
Center code: WUGSC
Web site: http://genome.wustl.edu/gsc/index.shtml
Contact: submissions@wustl.edu
----- Project Information -----
Center project name: M.BA0250E01
----- Summary Statistics -----
Sequencing vector: M13, 0%
Sequencing vector: plasmid, 100%
Chemistry: Dye-terminator ET; 0% of reads
Chemistry: Dye-terminator Big Dye; 100% of reads
Assembly program: Phrap; version 0.990319
Consensus quality: 217739 bases at least Q40
Consensus quality: 218068 bases at least Q30
Consensus quality: 218373 bases at least Q20
```

Query Match

29.7%; Score 211.499; DB 1; Length 221471;

```
Insert size: 193000; agarose-fp
Insert size: 227132; sum-of-contigs
Quality coverage: 14.88 in Q20 bases; agarose-fp
Quality coverage: 12.33 in Q20 bases; sum-of-contigs
-----
* NOTE: This is a 'working draft' sequence. It currently
* consists of 13 contigs. The true order of the pieces
* is not known and their order in this sequence record is
* arbitrary. Gaps between the contigs are represented as
* runs of N, but the exact sizes of the gaps are unknown.
* This record will be updated with the finished sequence
* as soon as it is available and the accession number will
* be preserved.
```

```
* 1 1509: contig of 1509 bp in length
* 1510 1509: gap of unknown length
* 1610 3423: contig of 1814 bp in length
* 3424 3524: gap of unknown length
* 3524 8474: contig of 4950 bp in length
* 8474 8574: gap of unknown length
* 8574 13990: contig of 5417 bp in length
* 13991 14090: gap of unknown length
* 14091 20220: contig of 6130 bp in length
* 20221 20321: gap of unknown length
* 20321 33395: contig of 13075 bp in length
* 33396 33495: gap of unknown length
* 33496 46731: contig of 13236 bp in length
* 46732 46832: gap of unknown length
* 46832 62618: contig of 15687 bp in length
* 62619 62619: gap of unknown length
* 62619 80893: contig of 18274 bp in length
* 80893 80993: gap of unknown length
* 80993 103313: contig of 22320 bp in length
* 103313 103413: gap of unknown length
* 103413 125915: contig of 22502 bp in length
* 125915 126015: gap of unknown length
* 126015 171459: contig of 45445 bp in length
* 171460 171559: gap of unknown length
* 171560 221471: contig of 49912 bp in length.
```

FEATURES

source

```
1..221471
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"
/chromosome="UNK"
/clone="RP23-250E1"
1..1509
/notes="assembly_name:Contig19"
1610..3423
/notes="assembly_name:Contig21"
3524..8473
/notes="assembly_name:Contig22"
8574..13990
/notes="assembly_name:Contig23"
14091..20220
/notes="assembly_name:Contig24"
20321..33395
/notes="assembly_name:Contig25"
33496..46731
/notes="assembly_name:Contig26"
46832..62518
/notes="assembly_name:Contig27"
62619..80892
/notes="assembly_name:Contig28"
80993..103312
/notes="assembly_name:Contig29"
103413..125914
/notes="assembly_name:Contig30"
126015..171459
/notes="assembly_name:Contig31"
171560..221471
/notes="assembly_name:Contig32"
```

misc_feature

```
misc_feature
1610..3423
/notes="assembly_name:Contig21"
3524..8473
/notes="assembly_name:Contig22"
8574..13990
/notes="assembly_name:Contig23"
14091..20220
/notes="assembly_name:Contig24"
20321..33395
/notes="assembly_name:Contig25"
33496..46731
/notes="assembly_name:Contig26"
46832..62518
/notes="assembly_name:Contig27"
62619..80892
/notes="assembly_name:Contig28"
80993..103312
/notes="assembly_name:Contig29"
103413..125914
/notes="assembly_name:Contig30"
126015..171459
/notes="assembly_name:Contig31"
171560..221471
/notes="assembly_name:Contig32"
```

Best Local Similarity 63.2%; Pred. No. 1.7;		Matches 456; Conservative 0; Mismatches 215; Indels 51; Gaps 9;	
Qy	1	AAATATCATCTATTATATCAATTAATCAATATGATGATCT-TTATTCCAATAACATTTGG	59
Db	87112	AAATATCAAGTTTATTAATCAATTAATCAATATGATGATCT-TTATTCCAATAACATTTGG	87053
Qy	60	GTATTGGGATTTAAATTTTCAACACACAGAGATGACAT--TTTTCCTGTCACATTTATT	117
Db	87052	GTGCTGCAATTTCCATTTTAAACACACAGAGATGACATTTTTCCTGTCACATTTATT	86993
Qy	118	ATTCTTGGTATGGAAGTATTTGGAGATCCAAATTCAGGAAGCAACATTTGGAGATGG	177
Db	86992	GTTCGTGACGTATGAAGCATTTTGGTGACACAAATTCAGGGAGAAATCCAGAGGAGAAAG	86933
Qy	178	CTACTTTCTATCAAGAAATAAAGAGAACACAGTCAACCCACACCAATCATCTTTAGAGA	237
Db	86932	CAACTTCCTATCAAGAAATAAAGAGAACCAACA---AGCCACAGAAATCATCTTTAGATGA	86876
Qy	238	CAGTGTGACTCCTACCAAGCTGTCAAAACACAGGCAAGGCATAGTTAAAGCA-----	292
Db	86875	GAAGTGGCTCCCTCCAAAGCATCCCAAACTACAGGCAAGGCACAGCAAGAGCAAT	86816
Qy	293	CGGAATCTTGACTCAAGAGGGTTAAATCTTGCTGCTGAAAGCTGGGGCAGGGGTGTAAG	352
Db	86815	GGGATCCCGGATTCAGAGGTTTCAATTCCTGCTGCTGAGGCTGGGGTGGGG-----	86764
Qy	353	AAAAACACTTAGATTTCAATGATTTAAATTTAAGGCAAAATACACATATTTAGTATTACCTT	412
Db	86763	-AATATGTTTACATCTACTAACAGTGAATTCAGGCAAGCAGACCTAACAGAAATCCCTT	86705
Qy	413	AGTGAATGATCCCTGTCATATATACAAATAAGGTGAATTTATAAGTACCCTATGCAAGTT	472
Db	86704	AGCATAACATA-CCCTGCCAGACAGCTGTTAAAGTGGCATCACAAATCCACAGCTC----	86650
Qy	473	GGCTGGACAGTTCTAAATTTGACCTTTTAAATTTTAAATCAGTAACTGAT-TTATCAC	531
Db	86649	-----TTTCACTTACTAAAGGAGCAGTAACAGCTTTATCTC	86612
Qy	532	TGGCTATGCTTAGATCTACAGGAGATCATATATTTGATACAAATAAAGAAAGTGT	591
Db	86611	TGGCTGTGCTGAATCTATGACACATGATAGAAATTTGATGCAACGAGGGGTAGTGT	86552
Qy	592	TCTCTCCCTTACAGAAATGACATTTTAAATGCGATACAGTTAGAAATATGACA	651
Db	86551	TCAGTGTCTTATGGAAGTATTTTACAGTGTATTTTACAGTGTATTTTACAGTGTATTT	86495
Qy	652	TTAGAAAGGAGATGACAGGAGAAAGGAGAAAGGAAATGTTGCCAAGGAAATAA	711
Db	86494	GGGAAGGAAATATAAGGGAAATGAGGAAGGAGCACTGAAGACTGTAAATGCTAATAA	86435
Qy	712	AA	713
Db	86434	TA	86433

Search completed: June 2, 2004, 16:22:42
Job time : 229 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2004, 16:29:06 ; Search time 54 Seconds
(without alignments)

4.019 Million cell updates/sec

Title: US-09-989-293A-376

Perfect score: 713

Sequence: 1 aatatacatctattatca.....tggtgcaaggaaaaaaa 713

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 207 seqs, 152209 residues

Total number of hits satisfying chosen parameters: 414

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 207 summaries

Database : rng376.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	713	100.0	713	1	AAZ65094
2	713	100.0	713	1	AAC58634
3	713	100.0	713	1	AAAS21480
4	713	100.0	713	1	AAAF44240
5	713	100.0	713	1	ABX77952
6	713	100.0	713	1	ABX80364
7	713	100.0	713	1	ACA69270
8	713	100.0	713	1	ACD24089
9	713	100.0	713	1	ABX90341
10	713	100.0	713	1	ABX64187
11	713	100.0	713	1	ACA67230
12	713	100.0	713	1	ACA64409
13	713	100.0	713	1	ACA03839
14	713	100.0	713	1	ABX83377
15	713	100.0	713	1	ABX80868
16	713	100.0	713	1	ACD44377
17	713	100.0	713	1	ABD42031
18	713	100.0	713	1	ABX79548
19	713	100.0	713	1	ACA93569
20	713	100.0	713	1	ABX81251
21	713	100.0	713	1	ACA04260
22	713	100.0	713	1	ACA93067
23	713	100.0	713	1	ABX17151
24	713	100.0	713	1	ACA68006
25	713	100.0	713	1	ACA88455
26	713	100.0	713	1	ACD81962
27	713	100.0	713	1	ADA45992
28	713	100.0	713	1	ADA76423
29	713	100.0	713	1	ADA19073
30	713	100.0	713	1	ADA61696
31	713	100.0	713	1	ADB19481
32	713	100.0	713	1	ADB28022
33	713	100.0	713	1	ADA86501

34	713	100.0	713	1	ADB16065	Human PRO polynucl
35	713	100.0	713	1	ADA37887	Human cDNA encodin
36	713	100.0	713	1	ADA47851	Human PRO polynucl
37	713	100.0	713	1	ADA21573	Human cDNA encodin
38	713	100.0	713	1	ADA10360	Human cDNA encodin
39	713	100.0	713	1	ADA67646	Human PRO polynucl
40	713	100.0	713	1	ADB30653	cDNA encoding huma
41	713	100.0	713	1	ADA85949	Novel human secret
42	713	100.0	713	1	ADA17904	cDNA encoding huma
43	713	100.0	713	1	ADA97161	Human PRO polynucl
44	713	100.0	713	1	ADA79485	Human PRO polynucl
45	713	100.0	713	1	ADA87604	Novel human secret
46	713	100.0	713	1	ADB16806	Human PRO polynucl
47	713	100.0	713	1	ADA28012	Human cDNA encodin
48	713	100.0	713	1	ADA91898	Novel human secret
49	713	100.0	713	1	ADB14961	Human PRO polynucl
50	713	100.0	713	1	ADB18922	Novel human secret
51	713	100.0	713	1	ADA94137	Human PRO polynucl
52	713	100.0	713	1	ADB20033	Novel human secret
53	713	100.0	713	1	ADB13345	Human PRO polynucl
54	713	100.0	713	1	ACD98660	Novel human secret
55	713	100.0	713	1	ADA94592	Human cDNA encodin
56	713	100.0	713	1	ADA74539	Human PRO polynucl
57	713	100.0	713	1	ADB24832	Human PRO polynucl
58	713	100.0	713	1	ADA82356	Human PRO polynucl
59	713	100.0	713	1	ADA75319	Human PRO polynucl
60	713	100.0	713	1	ADA85397	Novel human secret
61	713	100.0	713	1	ADA84845	Novel human secret
62	713	100.0	713	1	ADB30101	cDNA encoding huma
63	713	100.0	713	1	ADA80629	Human PRO polynucl
64	713	100.0	713	1	ADA75871	Human PRO polynucl
65	713	100.0	713	1	ADA38817	Human cDNA encodin
66	713	100.0	713	1	ADA47096	Human PRO polynucl
67	713	100.0	713	1	ADB25392	Human PRO polynucl
68	713	100.0	713	1	ADA93568	Human PRO polynucl
69	713	100.0	713	1	ADB26918	cDNA encoding huma
70	713	100.0	713	1	ADB31205	cDNA encoding huma
71	713	100.0	713	1	ADA92938	Human cDNA encodin
72	713	100.0	713	1	ADA61133	Homo sapiens, Nov
73	713	100.0	713	1	ADB24280	Human PRO polynucl
74	713	100.0	713	1	ADA96609	Human PRO polynucl
75	713	100.0	713	1	ADA81181	Human PRO polynucl
76	713	100.0	713	1	ADA96057	Human PRO polynucl
77	713	100.0	713	1	ADB26366	cDNA encoding huma
78	713	100.0	713	1	ADB21851	Novel human secret
79	713	100.0	713	1	ADA77630	Human PRO polynucl
80	713	100.0	713	1	ADB18370	cDNA encoding huma
81	713	100.0	713	1	ADA87053	Novel human secret
82	713	100.0	713	1	ADA88156	Novel human secret
83	713	100.0	713	1	ADA46544	Novel human secret
84	713	100.0	713	1	ADB28574	cDNA encoding huma
85	713	100.0	713	1	ADB29126	cDNA encoding huma
86	713	100.0	713	1	ACH65523	Human cDNA encodin
87	713	100.0	713	1	ADA77078	Human PRO polynucl
88	713	100.0	713	1	ADA22499	Human cDNA encodin
89	713	100.0	713	1	ADA88708	Novel human secret
90	713	100.0	713	1	ADA97713	Human PRO polynucl
91	713	100.0	713	1	ADB27470	cDNA encoding huma
92	713	100.0	713	1	ADB22403	Novel human secret
93	713	100.0	713	1	ACD39513	Human cDNA encodin
94	713	100.0	713	1	ADA06665	Human secreted/tra
95	713	100.0	713	1	ADA39358	Human cDNA encodin
96	713	100.0	713	1	ADA67094	Human PRO polynucl
97	713	100.0	713	1	ADB22955	Human PRO polynucl
98	713	100.0	713	1	ADB23728	Human PRO polynucl
99	713	100.0	713	1	ADA92450	Novel human secret
100	713	100.0	713	1	ADB15513	Human PRO polynucl
101	713	100.0	713	1	ADB36765	Novel human secret
102	713	100.0	713	1	ADB96384	Human PRO polynucl
103	713	100.0	713	1	ADB38213	Novel human secret
104	713	100.0	713	1	ADB66685	Novel human secret
105	713	100.0	713	1	ADB89765	Human PRO polynucl
106	713	100.0	713	1	ADB90497	Human PRO polynucl

107	713	100.0	713	1	ADBS39598	Novel human secret
108	713	100.0	713	1	ADBA47221	Novel human secret
109	713	100.0	713	1	ADBS86828	Human PRO polynucl
110	713	100.0	713	1	ADBS77433	Novel human secret
111	713	100.0	713	1	ADBS34590	Human PRO polynucl
112	713	100.0	713	1	ADBS35694	Human PRO polynucl
113	713	100.0	713	1	ADBS4038	Human PRO polynucl
114	713	100.0	713	1	ADBS35142	Human PRO polynucl
115	713	100.0	713	1	ADBS32246	Human PRO polynucl
116	713	100.0	713	1	ADBA46641	Novel human secret
117	713	100.0	713	1	ADCS57856	Human PRO polynucl
118	713	100.0	713	1	ADCS5220	Human PRO polynucl
119	713	100.0	713	1	ADCG12087	Human CDNA encodin
120	713	100.0	713	1	ADCS6509	Human CDNA encodin
121	713	100.0	713	1	ADCO75684	Human CDNA encodin
122	713	100.0	713	1	ADCG11554	Novel human secret
123	713	100.0	713	1	ADCS60514	Novel human secret
124	713	100.0	713	1	ADCT72061	Novel human secret
125	713	100.0	713	1	ADCG60040	Novel human secret
126	713	100.0	713	1	ADCS3047	Novel human secret
127	713	100.0	713	1	ADCS7401	Novel human secret
128	713	100.0	713	1	ADCG60592	Novel human secret
129	713	100.0	713	1	ADCS1067	Novel human secret
130	713	100.0	713	1	ADCG55594	Human PRO polynucl
131	713	100.0	713	1	ADCS45692	Novel human secret
132	713	100.0	713	1	ADCS31653	Novel human secret
133	713	100.0	713	1	ADCS91176	Novel human secret
134	713	100.0	713	1	ADCS6084	Novel human secret
135	713	100.0	713	1	ADCS86624	Novel human secret
136	713	100.0	713	1	ADCG14676	Novel human secret
137	713	100.0	713	1	ADDO80208	Novel human secret
138	713	100.0	713	1	ADDO31298	Novel human secret
139	713	100.0	713	1	ADCS90290	Novel human secret
140	713	100.0	713	1	ADCS82033	Human PRO polynucl
141	713	100.0	713	1	ADCG9709	CDNA encoding huma
142	713	100.0	713	1	ADCS48598	Human PRO polynucl
143	713	100.0	713	1	ADDO10127	Human PRO polynucl
144	713	100.0	713	1	ADDO7675	Novel human secret
145	713	100.0	713	1	ADDO4702	Human PRO polynucl
146	713	100.0	713	1	ADCS82566	Novel human secret
147	713	100.0	713	1	ADCS80658	Novel human secret
148	713	100.0	713	1	ADDO11165	Human PRO polynucl
149	713	100.0	713	1	ADCG48046	Human PRO polynucl
150	713	100.0	713	1	ADDO80746	Novel human secret
151	713	100.0	713	1	ADCS80106	Novel human secret
152	713	100.0	713	1	ADDO6995	Novel human secret
153	713	100.0	713	1	ADDO9575	Human PRO polynucl
154	713	100.0	713	1	ADCS83242	Human PRO polynucl
155	713	100.0	713	1	ADDO4117	Novel human secret
156	713	100.0	713	1	ADDS2428	CDNA encoding huma
157	713	100.0	713	1	ADDS2427	CDNA encoding huma
158	713	100.0	713	1	ADDS3167	Novel human secret
159	713	100.0	713	1	ADDS3719	Human PRO polynucl
160	713	100.0	713	1	ADDS5349	Human PRO polynucl
161	713	100.0	713	1	ADDS6307	Human PRO polynucl
162	713	100.0	713	1	ADDS1875	CDNA encoding huma
163	713	100.0	713	1	ADDO2674	Human PRO polynucl
164	713	100.0	713	1	ADDO2108	Human PRO polynucl
165	713	100.0	713	1	ADDS4290	Novel human secret
166	713	100.0	713	1	ADDS4745	Human PRO polynucl
167	713	100.0	713	1	ADDO92607	Human PRO polynucl
168	713	100.0	713	1	ADDO1503	Human PRO polynucl
169	713	100.0	713	1	ADDE04117	Novel human secret</

180	713	100.0	713	1	ADE19579	Human PRO polynucl
181	713	100.0	713	1	ADE19027	Human PRO polynucl
182	713	100.0	713	1	ADE43223	Human PRO polynucl
183	713	100.0	713	1	ADD96012	Human PRO polynucl
184	713	100.0	713	1	ADE22898	cdNA encoding huma
185	713	100.0	713	1	ADD79016	cdNA encoding huma
186	713	100.0	713	1	ADE26366	Novel human secret
187	713	100.0	713	1	ADE32366	Novel human secret
188	713	100.0	713	1	ADE42658	cdNA encoding huma
189	713	100.0	713	1	ADD80674	Human PRO polynucl
190	713	100.0	713	1	ADD89702	Human PRO polynucl
191	713	100.0	713	1	ADE40986	Human PRO polynucl
192	713	100.0	713	1	ADE04785	Human PRO polynucl
193	713	100.0	713	1	ADC81210	Novel human secret
194	713	100.0	713	1	ADD76658	Human PRO polynucl
195	713	100.0	713	1	ADD88022	Human PRO polynucl
196	713	100.0	713	1	ADD86426	Human PRO polynucl
197	713	100.0	713	1	ADD89702	Human PRO polynucl
198	713	100.0	713	1	ADE75874	Human PRO polynucl
199	713	100.0	713	1	ADE23450	cdNA encoding huma
200	713	100.0	713	1	ADE24002	cdNA encoding huma
201	713	100.0	713	1	ADE24645	cdNA encoding huma
202	713	100.0	713	1	ADD87470	Human PRO polynucl
203	713	100.0	713	1	ADE889336	Human PRO polynucl
204	713	100.0	713	1	ADE18475	Human PRO polynucl
205	705.6	99.0	5709	1	ADE88784	Human immune/haema
206	701.5	98.4	712	1	AAC91481	Human PRO1159 cDNA
207	332.8	46.7	336	1	AAK81284	Human immune/haema

RESULT 1

AAZ65094

ID AAZ65094 standard; cDNA; 713 BP.

XX

XX AAZ65094;

XX

DT 05-APR-2000 (first entry)

XX

DE Membrane-bound protein PRO1159 encoding cDNA.

XX

KW Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;

KW pharmaceutical; receptor immunoadhesin; gene mapping; ss.

XX

OS Homo sapiens.

XX

PN WO9963088-A2.

XX

PD 09-DEC-1999.

XX

PF 02-JUN-1999; 99WO-US012252.

XX

PR 02-JUN-1998; 98US-0087607P.

PR 02-JUN-1998; 98US-0087609P.

PR 02-JUN-1998; 98US-0087759P.

PR 03-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088021P.

PR 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088028P.

PR 04-JUN-1998; 98US-0088029P.

PR 04-JUN-1998; 98US-0088030P.

PR 04-JUN-1998; 98US-0088033P.

PR 04-JUN-1998; 98US-0088326P.

PR 05-JUN-1998; 98US-0088167P.

PR 05-JUN-1998; 98US-0088202P.

PR 05-JUN-1998; 98US-0088212P.

PR 05-JUN-1998; 98US-0088217P.

PR 09-JUN-1998; 98US-0088555P.

PR 10-JUN-1998; 98US-0088722P.

PR 10-JUN-1998; 98US-0088730P.

PR 10-JUN-1998; 98US-0088734P.

QY	61	TTTTGGGATTTTAAATTTCAACACAGCAGAGATGACATTTTTCGTCTACATTTATT	120	PF	17-APR-2002; 2002US-00124823.	XX
Db	61	TTTTGGGATTTTAAATTTCAACACAGCAGAGATGACATTTTTCGTCTACATTTATT	120	PR	31-MAR-1997; 97WO-US005230.	XX
QY	121	GTGTGATGTGAAGCTATTTGGAGATCCAAATTCAGGAGCAACACATTCGGAAATGGCTA	180	PR	12-JUN-1998; 98WO-US012456.	PR
Db	121	GTGTGATGTGAAGCTATTTGGAGATCCAAATTCAGGAGCAACACATTCGGAAATGGCTA	180	PR	14-JUL-1998; 98WO-US014552.	PR
QY	181	CTTCTCATCAAGAAATAAGAGAAACACACAGTCAACCCACACAAATCATCTTTTAAAGACAG	240	PR	28-AUG-1998; 98WO-US017883.	PR
Db	181	CTTCTCATCAAGAAATAAGAGAAACACACAGTCAACCCACACAAATCATCTTTTAAAGACAG	240	PR	10-SEP-1998; 98WO-US018824.	PR
QY	241	TGTGACTCTCAACAAAGCTGTCAAAACCAACAGCGCAAGGCATAGTTAAAGGACGGAATCT	300	PR	14-SEP-1998; 98WO-US019093.	PR
Db	241	TGTGACTCTCAACAAAGCTGTCAAAACCAACAGCGCAAGGCATAGTTAAAGGACGGAATCT	300	PR	14-SEP-1998; 98WO-US019094.	PR
QY	301	TGACTCAAGAGGGTTAAATTTCTGGTGCTGAAGCTGGGGCAGGGGTGTAAGAAAAACAC	360	PR	16-SEP-1998; 98WO-US019177.	PR
Db	301	TGACTCAAGAGGGTTAAATTTCTGGTGCTGAAGCTGGGGCAGGGGTGTAAGAAAAACAC	360	PR	16-SEP-1998; 98WO-US019330.	PR
QY	361	TTAGATTCATCATGTAATTTAAAGGCAATACACATATTAGTATACCTTAGTGTAT	420	PR	17-SEP-1998; 98WO-US019437.	PR
Db	361	TTAGATTCATCATGTAATTTAAAGGCAATACACATATTAGTATACCTTAGTGTAT	420	PR	07-OCT-1998; 98WO-US021141.	PR
QY	421	GTATCCCTGTCTATATACAAATAGGTGAAATTTAAAGTACCTATGCAAGTTGGCTGGAC	480	PR	29-OCT-1998; 98WO-US022991.	PR
Db	421	GTATCCCTGTCTATATACAAATAGGTGAAATTTAAAGTACCTATGCAAGTTGGCTGGAC	480	PR	29-OCT-1998; 98WO-US022992.	PR
QY	481	AGTTCTAAATGGACTTTTAAATTTTAAATCAGTAATCATCTATGCTAGT	540	PR	01-NOV-1998; 98WO-US024855.	PR
Db	481	AGTTCTAAATGGACTTTTAAATTTTAAATCAGTAATCATCTATGCTAGT	540	PR	01-DEC-1998; 98WO-US025108.	PR
QY	541	GCTTAGATCTACAGAGATCATATAATTTGATACAAATAAGAAAGTGTCTCTCCCC	600	PR	05-JAN-1999; 99WO-US000106.	PR
Db	541	GCTTAGATCTACAGAGATCATATAATTTGATACAAATAAGAAAGTGTCTCTCCCC	600	PR	08-MAR-1999; 99WO-US005028.	PR
QY	601	TTACAGAAATGCAATTTTAAATTCGAGATCAGTTAGAAATAGGAAATATGACATTAGAAAGG	660	PR	10-MAR-1999; 99WO-US005190.	PR
Db	601	TTACAGAAATGCAATTTTAAATTCGAGATCAGTTAGAAATAGGAAATATGACATTAGAAAGG	660	PR	2000WO-US006319.	PR
QY	661	AGAATGACAGGAGAAAGGAGGAAATGTTGCCAAGGAAAAAAA 713		PR	99WO-US008615.	PR
Db	661	AGAATGACAGGAGAAAGGAGGAAATGTTGCCAAGGAAAAAAA 713		PR	99WO-US010733.	PR

RESULT 202
ADE89336
ID ADE89336 standard; cDNA; 713 BP.
AC ADE89336;
XX
DT 29-JAN-2004 (first entry)
DE Human PRO polynucleotide #237.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199062-A1.
XX
PD 23-OCT-2003.
XX

28-FEB-2001; 2001US-00796498.
 PR 01-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 FA Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen MF, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2004-041360/04.
 DR P-PSDB; ADE89337.
 DR
 XX Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
 PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
 PT attack, various coagulation disorders, tumors.
 XX Claim 2; SEQ ID NO 473; 638pp; English.
 PS
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which

CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 713 BP; 262 A; 105 C; 134 G; 212 T; 0 U; 0 Other;
 Query Match 100.0%; Score 713; DB 1; Length 713;
 Best Local Similarity 100.0%; Pred. No. 1.4;
 Matches 713; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AATATATCATCTATTATCATTAATCAATAAATGTTCTTTTATCCCAATAACATTGGG 60
 DB 1 AATATATCATCTATTATCATTAATCAATAAATGTTCTTTTATCCCAATAACATTGGG 60
 QY 61 TTTTGGGATTTTAAATTTTCAAAACACAGCAGAAATGACATTTTCTGTCTACTATTATT 120
 DB 61 TTTTGGGATTTTAAATTTTCAAAACACAGCAGAAATGACATTTTCTGTCTACTATTATT 120
 QY 121 GTTGGTATGTGAAGCTATTGTGGAGATCCAAATTCAGGAAGCAACATTTGGAGATGGCTA 180
 DB 121 GTTGGTATGTGAAGCTATTGTGGAGATCCAAATTCAGGAAGCAACATTTGGAGATGGCTA 180
 QY 181 CTTTCTATCAAGAAATTAAGAGAACCCACAGTCAACCCACACATCATCTTTAGAAGACAG 240
 DB 181 CTTTCTATCAAGAAATTAAGAGAACCCACAGTCAACCCACACATCATCTTTAGAAGACAG 240
 QY 241 TGTGACTCCTCAACAAAGCTGTCAAAACACAGGCAAGGGCATAGTTAAAGGACGGAATCT 300
 DB 241 TGTGACTCCTCAACAAAGCTGTCAAAACACAGGCAAGGGCATAGTTAAAGGACGGAATCT 300
 QY 301 TGACTCAAGAGGGTTAAATTTCTGGTCTGAAGCTGGGCGAGGGGTAAAGAAAACAC 360
 DB 301 TGACTCAAGAGGGTTAAATTTCTGGTCTGAAGCTGGGCGAGGGGTAAAGAAAACAC 360
 QY 361 TTAGATTCAATGATGTTAAATTTAAGGCAAAATACATATTAGTATTACCTTAGTGTAA 420
 DB 361 TTAGATTCAATGATGTTAAATTTAAGGCAAAATACATATTAGTATTACCTTAGTGTAA 420
 QY 421 GTATCCTGTCTATATACAAATTAAGTGAAATTAAGTACCTTATGCTAGTTGGCTGGAC 480
 DB 421 GTATCCTGTCTATATACAAATTAAGTGAAATTAAGTACCTTATGCTAGTTGGCTGGAC 480
 QY 481 AGTCTCAATTTGACGCTTTTAAATTTTAAATTCAGTAACTGATTTATCACTGGCTATGT 540
 DB 481 AGTCTCAATTTGACGCTTTTAAATTTTAAATTCAGTAACTGATTTATCACTGGCTATGT 540
 QY 541 GCTTAGATCTACAGGAGATCATATAATTTGATACAAATTAAGAAAGTGTCTCTCCCC 600
 DB 541 GCTTAGATCTACAGGAGATCATATAATTTGATACAAATTAAGAAAGTGTCTCTCCCC 600
 QY 601 TTACAGATTTGACATTTTAAATTCGATACAGTTAGATAGGAATATGACATTAGAAAG 660
 DB 601 TTACAGATTTGACATTTTAAATTCGATACAGTTAGATAGGAATATGACATTAGAAAG 660
 QY 661 AAGAATCACAGGAGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAG 713
 DB 661 AAGAATCACAGGAGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAG 713
 RESULT 203
 ADE18475
 ID ADE18475 standard; cDNA; 713 BP.
 XX
 AC ADE18475;
 XX
 DT 29-JAN-2004 (first entry)
 XX Human PRO polynucleotide #237.
 XX
 XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003194794-A1.
XX PD 16-OCT-2003.
XX PF 17-APR-2002; 2002US-00125805.
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 01-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.

PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00806889.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828365.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2004-021079/02.

P-PSDB; ADE18476.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or PRO4978, for use in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy.

Claim 2; SEQ ID NO 473; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a

medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX
SQ Sequence 713 BP; 262 A; 105 C; 134 G; 212 T; 0 U; 0 Other;

Query Match		100.0%;	Score 713;	DB 1;	Length 713;
Best Local Similarity		100.0%;	Pred. No. 1.4;	0;	
Matches 713;		Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	AAATATATCATCTATTTATCATTAATCAATATGTAATCTTTTATTCATTAACATTAATGGG	60		
Db	1	AAATATATCATCTATTTATCATTAATCAATATGTAATCTTTTATTCATTAACATTAATGGG	60		
QY	61	TTTGGGATTTTAAATTTTAAACACAGAGATGACATTTTCTGTCTACTATTTATTT	120		
Db	61	TTTGGGATTTTAAATTTTAAACACAGAGATGACATTTTCTGTCTACTATTTATTT	120		
QY	121	GTTCGGATGTAAGCTATTTGGAGATCAATTCAGGAAGCAACATTCGAGATGGCTA	180		
Db	121	GTTCGGATGTAAGCTATTTGGAGATCAATTCAGGAAGCAACATTCGAGATGGCTA	180		
QY	181	CTTTCTATCAAGAATAAAGAGAACCAAGTCACACCAACATCACTTTTAGAAGACAG	240		
Db	181	CTTTCTATCAAGAATAAAGAGAACCAAGTCACACCAACATCACTTTTAGAAGACAG	240		
QY	241	TGTGACTCTACCAAGCTGTCAAAACACAGGCAAGGCGTAGTTAAGACCGAATCT	300		
Db	241	TGTGACTCTACCAAGCTGTCAAAACACAGGCAAGGCGTAGTTAAGACCGAATCT	300		
QY	301	TGACTCAAGAGGGTTAATCTTGTGCTGAAGCCTGGGGCAGGGGTGTAAGAAAAACAC	360		
Db	301	TGACTCAAGAGGGTTAATCTTGTGCTGAAGCCTGGGGCAGGGGTGTAAGAAAAACAC	360		
QY	361	TTAGATTCATGATGTGTAATTTAAGGCAATACACATATTAGTATTACCTTAGTGTAT	420		
Db	361	TTAGATTCATGATGTGTAATTTAAGGCAATACACATATTAGTATTACCTTAGTGTAT	420		
QY	421	GTATCCCTGTATATATACATTAAGTGAATTAAGTACCTATGAGTTGGCTGGAC	480		
Db	421	GTATCCCTGTATATATACATTAAGTGAATTAAGTACCTATGAGTTGGCTGGAC	480		
QY	481	AGTTCTAAATGGACCTTTATTAATTTTAAATCAGTAATGATTTATCAGTGGCTATGT	540		
Db	481	AGTTCTAAATGGACCTTTATTAATTTTAAATCAGTAATGATTTATCAGTGGCTATGT	540		
QY	541	GCTTAGATCTACAGGAGATCATATATTTTGTATACAAATTAAGAAATATGACATTAGAAAG	600		
Db	541	GCTTAGATCTACAGGAGATCATATATTTTGTATACAAATTAAGAAATATGACATTAGAAAG	600		
QY	601	TTACAGAAATGACATTTTAAATGCGGATACAGTTAGTAATAGGAAATATGACATTAGAAAG	660		
Db	601	TTACAGAAATGACATTTTAAATGCGGATACAGTTAGTAATAGGAAATATGACATTAGAAAG	660		
QY	661	AAAGATGACAGGAGAAAGAAAGGAAAGGAAATGTTGCCAAGGAAAAA	713		
Db	661	AAAGATGACAGGAGAAAGAAAGGAAAGGAAATGTTGCCAAGGAAAAA	713		

RESULT 204
ADE88784
ID ADE88784 standard; CDNA; 713 BP.
XX ADE88784;
AC ADE88784;
XX
DT 29-JAN-2004 (first entry)
DE Human PRO polynucleotide #237.
XX
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
XX
XX US2003199054-A1.
XX
XX 23-OCT-2003.
XX
XX 12-APR-2002; 2002US-00121054.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 13-SEP-1999; 99WO-US020594.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US000365.
 PR 18-FEB-2000; 2000WO-US0004341.
 PR 18-FEB-2000; 2000WO-US0004342.
 PR 22-FEB-2000; 2000WO-US0004414.
 PR 24-FEB-2000; 2000WO-US0004914.
 PR 24-FEB-2000; 2000WO-US0005004.
 PR 01-MAR-2000; 2000WO-US0005601.
 PR 02-MAR-2000; 2000WO-US0005746.
 PR 02-MAR-2000; 2000WO-US0005841.
 PR 15-MAR-2000; 2000WO-US0006884.
 PR 20-MAR-2000; 2000WO-US0007377.
 PR 21-MAR-2000; 2000WO-US0007532.
 PR 30-MAR-2000; 2000WO-US0008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023528.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 PA (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski P, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2004-041356/04.
 DR P-PSDB; ADS88785.
 XX
 DR
 XX
 PT Novel secreted and transmembrane polypeptides, PRO useful for treating
 PT bone disorders, arthritis, heart attack, injuries, tumors, and
 PT stimulating release of TNF-alpha from human blood.
 XX
 PS Claim 2; SEQ ID NO 473; 638pp; English.
 PS
 XX The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC anisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalasaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 713 BP; 262 A; 105 C; 134 G; 212 T; 0 U; 0 Other;
 Query Match 100.0%; Score 713; DB 1; Length 713;
 Best Local Similarity 100.0%; Pred. No. 1.4;
 Matches 713; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AATATATCATCTATTATCATTAATCAATATGATTTCTTTTATCCCAATACATTGGG 60
 DB 1 AATATATCATCTATTATCATTAATCAATATGATTTCTTTTATCCCAATACATTGGG 60
 QY 61 TTTTGGGATTTTAAATTTTCAAACACAGCAGAAATGACATTTTCTGTCACTATTATT 120
 DB 61 TTTTGGGATTTTAAATTTTCAAACACAGCAGAAATGACATTTTCTGTCACTATTATT 120
 QY 121 GTTGTATGTGAAGCTATTGTGAGATCCCAATTCAGGAGCAGACATTTGGAGATGGCTA 180
 DB 121 GTTGTATGTGAAGCTATTGTGAGATCCCAATTCAGGAGCAGACATTTGGAGATGGCTA 180
 QY 181 CTTTCTATCAAGAAATAAAGAGAACCAAGTCAACCCACACATCATCTTTTGAAGACAG 240
 DB 181 CTTTCTATCAAGAAATAAAGAGAACCAAGTCAACCCACACATCATCTTTTGAAGACAG 240
 QY 241 TGTGACTCCTACCAAGCTGTCAAACCCAGGAGGAGGATAGTTAAAGGACGGAATCT 300
 DB 241 TGTGACTCCTACCAAGCTGTCAAACCCAGGAGGAGGATAGTTAAAGGACGGAATCT 300
 QY 301 TGACTCAAGAGGTTAAATCTTGGTCTGAAGCCTGGGCGAGGCTGTAAAGAAAACAC 360
 DB 301 TGACTCAAGAGGTTAAATCTTGGTCTGAAGCCTGGGCGAGGCTGTAAAGAAAACAC 360
 QY 361 TTAGATTCAATGATTGTAATTTAAGGCAATACATATTAGTATTACCTTAGTGTAA 420
 DB 361 TTAGATTCAATGATTGTAATTTAAGGCAATACATATTAGTATTACCTTAGTGTAA 420
 QY 421 GTATCCCTGTCTATATACAAATTAAGGTGAATTAAGTACCTTACCTTAGTGTGAC 480
 DB 421 GTATCCCTGTCTATATACAAATTAAGGTGAATTAAGTACCTTACCTTAGTGTGAC 480
 QY 481 AGTTCTAAATTTGGACTTTTAAATTTTAAATTCAGTAACTGATTATACCTGCTATCT 540
 DB 481 AGTTCTAAATTTGGACTTTTAAATTTTAAATTCAGTAACTGATTATACCTGCTATCT 540

Db 481 AGTTCTAAATGGACTTTTATTAATTTTAAAACTAGTAATGATTAATCACTGGCTATGT 540
 QY 541 GCTTATGATCTACAGGAGATCATATAATTTGATACAAATAAAGAAAGTGTCTCTCCCC 600
 Db 541 GCTTATGATCTACAGGAGATCATATAATTTGATACAAATAAAGAAAGTGTCTCTCCCC 600
 QY 601 TTACAGAATTCACATTTTAAATCGGATACACATAGTTAGAAATATGACATTAGAAAG 660
 Db 601 TTACAGAATTCACATTTTAAATCGGATACACATAGTTAGAAATATGACATTAGAAAG 660
 QY 661 AAGAATGACAGGAGAGAAAGAAAGGAAATGTTGCCAAGAAAAAAA 713
 Db 661 AAGAATGACAGGAGAGAAAGAAAGGAAATGTTGCCAAGAAAAAAA 713

RESULT 205
 AAK81282/c
 ID AAK81282 standard; DNA; 5709 BP.
 XX
 AC AAK81282;
 XX
 DT 07-NOV-2001 (first entry)
 XX
 DE Human immune/haematopoietic antigen genomic sequence SEQ ID NO:36094.
 KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
 KW cytostatic; gene therapy; vaccine; metastasis; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200157182-A2.
 XX
 PD 09-AUG-2001.
 XX
 PF 17-JAN-2001; 2001WO-US001354.
 XX

PR 01-SEP-2000; 2000US-0229343P.
 PR 01-SEP-2000; 2000US-0229344P.
 PR 01-SEP-2000; 2000US-0229345P.
 PR 05-SEP-2000; 2000US-0229509P.
 PR 05-SEP-2000; 2000US-0229513P.
 PR 06-SEP-2000; 2000US-0230437P.
 PR 06-SEP-2000; 2000US-0230438P.
 PR 08-SEP-2000; 2000US-0231242P.
 PR 08-SEP-2000; 2000US-0231243P.
 PR 08-SEP-2000; 2000US-0231244P.
 PR 08-SEP-2000; 2000US-0231413P.
 PR 08-SEP-2000; 2000US-0231414P.
 PR 08-SEP-2000; 2000US-0232080P.
 PR 08-SEP-2000; 2000US-0232081P.
 PR 12-SEP-2000; 2000US-0231968P.
 PR 14-SEP-2000; 2000US-0232397P.
 PR 14-SEP-2000; 2000US-0232398P.
 PR 14-SEP-2000; 2000US-0232399P.
 PR 14-SEP-2000; 2000US-0232400P.
 PR 14-SEP-2000; 2000US-0232401P.
 PR 14-SEP-2000; 2000US-0233063P.
 PR 14-SEP-2000; 2000US-0233064P.
 PR 14-SEP-2000; 2000US-0233065P.
 PR 21-SEP-2000; 2000US-0234223P.
 PR 21-SEP-2000; 2000US-0234274P.
 PR 25-SEP-2000; 2000US-0234997P.
 PR 25-SEP-2000; 2000US-0234998P.
 PR 26-SEP-2000; 2000US-0235484P.
 PR 27-SEP-2000; 2000US-0235834P.
 PR 27-SEP-2000; 2000US-0235836P.
 PR 29-SEP-2000; 2000US-0236327P.
 PR 29-SEP-2000; 2000US-0236367P.
 PR 29-SEP-2000; 2000US-0236368P.
 PR 29-SEP-2000; 2000US-0236369P.
 PR 29-SEP-2000; 2000US-0236370P.
 PR 02-OCT-2000; 2000US-0236802P.
 PR 02-OCT-2000; 2000US-0237037P.
 PR 02-OCT-2000; 2000US-0237038P.
 PR 02-OCT-2000; 2000US-0237039P.
 PR 02-OCT-2000; 2000US-0237040P.
 PR 13-OCT-2000; 2000US-0239353P.
 PR 13-OCT-2000; 2000US-0239337P.
 PR 20-OCT-2000; 2000US-0240960P.
 PR 20-OCT-2000; 2000US-0241221P.
 PR 20-OCT-2000; 2000US-0241785P.
 PR 20-OCT-2000; 2000US-0241786P.
 PR 20-OCT-2000; 2000US-0241787P.
 PR 20-OCT-2000; 2000US-0241808P.
 PR 20-OCT-2000; 2000US-0241809P.
 PR 20-OCT-2000; 2000US-0241826P.
 PR 01-NOV-2000; 2000US-0244617P.
 PR 08-NOV-2000; 2000US-0246474P.
 PR 08-NOV-2000; 2000US-0246475P.
 PR 08-NOV-2000; 2000US-0246476P.
 PR 08-NOV-2000; 2000US-0246477P.
 PR 08-NOV-2000; 2000US-0246478P.
 PR 08-NOV-2000; 2000US-0246523P.
 PR 08-NOV-2000; 2000US-0246524P.
 PR 08-NOV-2000; 2000US-0246525P.
 PR 08-NOV-2000; 2000US-0246526P.
 PR 08-NOV-2000; 2000US-0246527P.
 PR 08-NOV-2000; 2000US-0246528P.
 PR 08-NOV-2000; 2000US-0246532P.
 PR 08-NOV-2000; 2000US-0246609P.
 PR 08-NOV-2000; 2000US-0246610P.
 PR 08-NOV-2000; 2000US-0246611P.
 PR 17-NOV-2000; 2000US-0249207P.
 PR 17-NOV-2000; 2000US-0249208P.
 PR 17-NOV-2000; 2000US-0249209P.
 PR 17-NOV-2000; 2000US-0249210P.
 PR 17-NOV-2000; 2000US-0249211P.
 PR 17-NOV-2000; 2000US-0249212P.

PR	17-NOV-2000;	2000US-0249213P.	
PR	17-NOV-2000;	2000US-0249214P.	
PR	17-NOV-2000;	2000US-0249215P.	
PR	17-NOV-2000;	2000US-0249216P.	
PR	17-NOV-2000;	2000US-0249217P.	
PR	17-NOV-2000;	2000US-0249218P.	
PR	17-NOV-2000;	2000US-0249219P.	
PR	17-NOV-2000;	2000US-0249220P.	
PR	17-NOV-2000;	2000US-0249221P.	
PR	17-NOV-2000;	2000US-0249222P.	
PR	17-NOV-2000;	2000US-0249223P.	
PR	17-NOV-2000;	2000US-0249224P.	
PR	17-NOV-2000;	2000US-0249225P.	
PR	17-NOV-2000;	2000US-0249226P.	
PR	17-NOV-2000;	2000US-0249227P.	
PR	17-NOV-2000;	2000US-0249228P.	
PR	17-NOV-2000;	2000US-0249229P.	
PR	17-NOV-2000;	2000US-0249230P.	
PR	01-DEC-2000;	2000US-0250160P.	
PR	01-DEC-2000;	2000US-0250391P.	
PR	05-DEC-2000;	2000US-0251030P.	
PR	05-DEC-2000;	2000US-0251030P.	
PR	05-DEC-2000;	2000US-0251988P.	
PR	06-DEC-2000;	2000US-0256719P.	
PR	08-DEC-2000;	2000US-0251479P.	
PR	08-DEC-2000;	2000US-0251856P.	
PR	08-DEC-2000;	2000US-0251868P.	
PR	08-DEC-2000;	2000US-0251869P.	
PR	08-DEC-2000;	2000US-0251989P.	
PR	08-DEC-2000;	2000US-0251990P.	
PR	11-DEC-2000;	2000US-0254097P.	
PR	05-JAN-2001;	2001US-0259678P.	
XX	(HUMA-)	HUMAN GENOME SCI INC.	
XX			
XX	Rosen CA, Barash SC, Ruben SM;		
XX	WPI; 2001-483426/52.		
XX			
DX	Nucleic acids encoding human immune/hematopoietic antigen polypeptides,		
DX	useful for preventing, diagnosing and/or treating cancers and metastasis.		
XX			
XX	Disclosure; SEQ ID NO 36094; 307lpp + Sequence Listing; English.		
XX			
CC	AAK54951 to AAK64702 encode the human immune/hematopoietic antigen (I)		
CC	amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic		
CC	activity, and can be used in gene therapy and vaccine production. (I)		
CC	proteins and polynucleotides may be used in the prevention, diagnosis and		
CC	treatment of diseases associated with inappropriate (I) expression. For		
CC	example, they may be used to treat disorders associated with decreased		
CC	expression by rectifying mutations or deletions in a patient's genome		
CC	that affect the activity of (I) by expressing inactive proteins or to		
CC	supplement the patients own production of (I). Additionally, (I)		
CC	polynucleotides may be used to produce the secreted (I), by inserting the		
CC	nucleic acids into a host cell and culturing the cell to express the		
CC	protein. (I) proteins and polynucleotides may be used to prevent,		
CC	diagnose and treat immune/hematopoietic-related diseases, especially		
CC	cancers and cancer metastases of hematopoietic-derived cells. AAK64703		
CC	to AAK87694 represent human immune/hematopoietic antigen genomic		
CC	sequences from the present invention. AAK54942 to AAK54950 and AAM82169		
CC	represent sequences used in the exemplification of the present invention		
XX			
XX	Sequence 5709 BP; 1849 A; 1109 C; 988 G; 1763 T; 0 U; 0 Other;		
XX			
XX	Query Match	99.0%; Score 705.6; DB 1; Length 5709;	
XX	Best Local Similarity	99.4%; Pred. No. 0.19;	
XX	Matches 708; Conservative	0; Mismatches 4; Indels 0; Gaps 0;	
Qy	1	AATATATCATCTATTATTCATTATCAATATGATATGATTCCTTTTATTCCAATAACATTTGGG	60
Db	2310	AATATATCATCTATTATTCATTATCAATATGATATGATTCCTTTTATTCCAATAACATTTGGG	2251
Qy	61	TTTTTGGGATTTTAAATTTTCAAACACAGCAATGACATTTTTTTCTGTCACTATTATTATT	120
Db	2250	TTTTTGGGATTTTAAATTTTCAAACACAGCAATGACATTTTTTTCTGTCACTATTATTATT	2191
Qy	121	GTTCGGTATGGAAGCTATTTGGAGATCCAAATTCAGGAAGCAACACATTCGAGAAATGGCTA	180
Db	2190	GTTCGGTATGGAAGCTATTTGGAGATCCAAATTCAGGAAGCAACACATTCGAGAAATGGCTA	2131

181	QY	181	CTTCTCTATCAAGAAATAAGAGAACCAAGCTCAACCCACACAATCATCTTTAGAACACAG	240
2130	Db	2130	CTTCTCTATCAAGAAATAAGAGAACCCACAGTCAACCCACACAATCATCTTTAGAACACAG	2071
241	QY	241	TGTGACTCTCTACCAAGCTGTCAAAACACACAGCGAAGGCGCTAGTTAAAGGACGGAATCT	300
2070	Db	2070	TGTGACTCTCTACCAAGCTGTCAAAACACACAGCGAAGGCGCTAGTTAAAGGACGGAATCT	2011
301	QY	301	TGACTCAAGAGGGTTAAATCTTTGGTGTCTGAAGCTCTGGGCGAGGGGTGTAAAGAAAAACAC	360
2010	Db	2010	TGACTCAAGAGGGTTAAATCTTTGGTGTCTGAAGCTCTGGGCGAGGGGTGTAAAGAAAAACAC	1951
361	QY	361	TTAGATTCAATGATTCTTAATTTAAAGGCGAAATACACATATTAGTATTACCTTAGTGTAAAT	420
1950	Db	1950	TTAGATTCAATGATTCTTAATTTAAAGGCGAAATACACATATTAGTATTACCTTAGTGTAAAT	1891
421	QY	421	GTATCCCTCTCATATATACATAAAGGTGAAATTTATAAGTACCCCTATGCAGTTGGCTGGAC	480
1890	Db	1890	GTATCCCTCTCATATATACATAAAGGTGAAATTTATAAGTACCCCTATGCAGTTGGCTGGAC	1831
481	QY	481	AGTTCTAAATGGACTTTTAAATTTTAAATTCAGTAACTGATTTATCATCTGGCTATGT	540
1830	Db	1830	AGTTCTAAATGGACTTTTAAATTTTAAATTCAGTAACTGATTTATCATCTGGCTATGT	1771
541	QY	541	GCTTAGATCTACAGGAGATCATATATTTTGCATACAAATAAAGAAAAGTCTCTCTCCCC	600
1770	Db	1770	GCTTAGATCTACAGGAGATCATATATTTTGCATACAAATAAAGAAAAGTCTCTCTCCCC	1711
601	QY	601	TTACAGAATTGCATTTTAAATCGGATACAGTTAGAAATAGGAAATATGACATTAGAAAAG	660
1710	Db	1710	TTACAGAATTGCATTTTAAATCGGATACAGTTAGAAATAGGAAATATGACATTAGAAAAG	1651
661	QY	661	AGAATTACAGGAGAGAAAGAAAGAGGGAATTTGTTCCCAAGGAAAAAAA	712
1650	Db	1650	AGAATTACAGGAGAGAAAGAAAGAGGGAATTTGTTCCCAAGGAAAAAAA	1599
RESULT 206				
AAC91481				
ID AAC91481 standard; cDNA; 712 BP.				
XX	AC	AAC91481;		
XX	AC			
XX	DT	21-MAR-2001 (first entry)		
XX	XX	Human PRO1159 cDNA.		
XX	XX			
XX	KW	Human; PRO; antiinflammatory; dermatological; antiarthritic;		
XX	KW	antirheumatic; cardiant; antianemic; immunosuppressive; antithyroid;		
XX	KW	antidiabetic; nootropic; neuroprotective; hepatotropic; virucide;		
XX	KW	antiallergic; antiasthmatic; immune related disorder;		
XX	KW	hepatobiliary disease; autoimmune disease; allergy; ss.		
OS	XX	Homo sapiens.		
XX	XX			
XX	PN	WO200073452-A2.		
XX	XX			
XX	PD	07-DEC-2000.		
XX	PF			
XX	XX	02-JUN-2000; 2000WO-US015264.		
XX	PR	02-JUN-1999; 99WO-US012252.		
XX	PR	20-JUL-1999; 99US-0144732P.		
XX	PR	28-JUL-1999; 99US-0144758P.		
XX	PR	28-JUL-1999; 99US-0146222P.		
XX	PR	01-SEP-1999; 99WO-US020111.		
XX	PR	15-SEP-1999; 99WO-US021090.		
XX	PR	15-SEP-1999; 99WO-US021547.		
XX	PR	20-OCT-1999; 99US-0162506P.		
XX	PR	30-NOV-1999; 99WO-US028313.		
XX	PR	01-DEC-1999; 99WO-US028634.		
XX	PR	02-DEC-1999; 99WO-US028551.		

PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225367P.
PR 14-AUG-2000; 2000US-0225368P.
PR 14-AUG-2000; 2000US-0225370P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225578P.
PR 14-AUG-2000; 2000US-0225758P.
PR 18-AUG-2000; 2000US-0225759P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226688P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233083P.
PR 14-SEP-2000; 2000US-0233084P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234224P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0248524P.
PR 08-NOV-2000; 2000US-0248525P.
PR 08-NOV-2000; 2000US-0248526P.
PR 08-NOV-2000; 2000US-0248527P.
PR 08-NOV-2000; 2000US-0248528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
(HUMA-) HUMAN GENOME SCI INC.
Rosen CA, Barash SC, Ruben SM;
WPI; 2001-483426/52.
Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
useful for preventing, diagnosing and/or treating cancers and metastasis.
Disclosure; SEQ ID NO 36096; 3071pp + Sequence Listing; English.
AAK54951 to AAK64702 encode the human immune/hematopoietic antigen (I)
amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
activity, and can be used in gene therapy and vaccine production. (I)
proteins and polynucleotides may be used in the prevention, diagnosis and
treatment of diseases associated with inappropriate (I) expression. For
example, they may be used to treat disorders associated with decreased
expression by rectifying mutations or deletions in a patient's genome
that affect the activity of (I) by expressing inactive proteins or to

CC supplement the patients own production of (I). Additionally, (I)
 CC polynucleotides may be used to produce the secreted (I), by inserting the
 CC nucleic acids into a host cell and culturing the cell to express the
 CC protein. (I) proteins and polynucleotides may be used to prevent,
 CC diagnose and treat immune/haematopoietic-related diseases, especially
 CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703
 CC to AAK87694 represent human immune/haematopoietic antigen genomic
 CC sequences from the present invention. AAK54942 to AAK54950 and AAK82169
 CC represent sequences used in the exemplification of the present invention
 XX
 SQ Sequence 336 BP; 98 A; 66 C; 49 G; 123 T; 0 U; 0 Other;

Query Match	46.7%;	Score 332.8;	DB 1;	Length 336;
Best Local Similarity	99.4%;	Pred. No. 98;		
Matches 334;	Conservative	0;	Mismatches 2;	Indels 0;
Gaps	0;			

QY	252	CCAAAGCTGTCAAAACCAACAGGCAAGGCAATAGTTAAAGGACGGAACTCTGACTCAAGAG	311
DB	336	CCAAAGCTGTCAAAACCAACAGGCAAGGCAATAGTTAAAGGACGGAACTCTGACTCAAGAG	277
QY	312	GGTTAAATCTTGGTCTGAAGCTGGGCGAGGGGTAAAGAAACACCTTAGATTCAAT	371
DB	276	GGTTAAATCTTGGTCTGAAGCTGGGCGAGGGGTAAAGAAACACCTTAGATTCAAT	217
QY	372	GATTGTAATTTAAGGCAAAATACACATATTAGTATTACCTTAGTGTATGTATCCCTGTC	431
DB	216	GATTGTAATTTAAGGCAAAATACACATATTAGTATTACCTTAGTGTATGTATCCCTGTC	157
QY	432	ATATATACATTAAGTGAATTTAAGTACCTATGAGTGGCTGGACAGTTCTAAAT	491
DB	156	ATATATACATTAAGTGAATTTAAGTACCTATGAGTGGCTGGACAGTTCTAAAT	97
QY	492	GGACCTTTATTTTAAATCACTGATTTATCACTGGCTATGTGCTTAGATCTA	551
DB	96	GGACCTTTATTTTAAATCACTGATTTATCACTGGCTATGTGCTTAGATCTA	37
QY	552	CAGGAGATCATATAATTTGATACAAATAAGAAAA	587
DB	36	CAGGAGATCATATAATTTGATACAAATAAGAAAA	1

Search completed: June 2, 2004, 16:30:22
 Job time : 75 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 29, 2004, 09:11:03 ; Search time 102 Seconds
(without alignments)
3879.216 Million cell updates/sec

Title: US-09-989-293A-376
Perfect score: 713
Sequence: 1 aatatcatcatattatca.....tggtgccaaggaaaaaaa 713

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 682709 seqs, 277475446 residues

Total number of hits satisfying chosen parameters: 1365418

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 65000 summaries

Database : Issued Patents NA:
1: /cgn2_6/prodata/2/ina/5A_COMB.seq:
2: /cgn2_6/prodata/2/ina/5B_COMB.seq:
3: /cgn2_6/prodata/2/ina/6A_COMB.seq:
4: /cgn2_6/prodata/2/ina/6B_COMB.seq:
5: /cgn2_6/prodata/2/ina/PCTUS_COMB.seq:
6: /cgn2_6/prodata/2/ina/backfiles1.seq:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	77.6	10.9	2298	3	US-08-772-440-1
2	75.2	10.5	528	3	US-08-772-440-7
3	46.6	6.5	7218	1	US-08-232-463-14
4	45.2	6.3	832	4	US-09-621-976-2813
5	44	6.2	640681	4	US-09-790-988-1
6	40.4	5.7	5847	4	US-09-920-672-10
7	39.6	5.6	20674	4	US-09-641-638-651
8	39.2	5.5	8920	2	US-08-446-855A-1
9	39.2	5.5	8920	3	US-09-150-741-1
10	38.6	5.4	4526	1	US-07-855-412B-4
11	38.6	5.4	4526	2	US-08-308-887A-4
12	38.6	5.4	4526	3	US-08-881-094-4
13	38.4	5.4	58407	4	US-08-916-421B-2
14	38	5.3	19233	4	US-10-204-708-45
15	37.8	5.3	1537	4	US-09-626-959D-2
16	37.8	5.3	202001	4	US-09-734-674-3
17	37.6	5.3	1335	4	US-09-543-681A-1450
18	37.4	5.2	275	4	US-08-585-593A-42
19	37.4	5.2	361	3	US-09-018-584A-9
20	37.4	5.2	2422	1	US-07-867-106-5
21	37.4	5.2	5852	1	US-07-867-106-2
22	37.4	5.2	786431	4	US-09-751-389-3
23	37.2	5.2	832	4	US-09-621-976-2813
24	37.2	5.2	9064	4	US-08-961-527-17
25	37	5.2	2110	3	US-09-419-459-1
26	37	5.2	10160	4	US-09-097-319A-8
27	37	5.2	10323	4	US-09-280-428A-11

c	28	37	5.2	11784	4	US-09-097-319A-9	Sequence 9, Appli
c	29	37	5.2	11991	4	US-09-097-319A-10	Sequence 10, Appli
c	30	37	5.2	24595	6	5428147-1	Patent No. 5428147
c	31	36.8	5.2	10467	4	US-10-204-708-2	Sequence 2, Appli
c	32	36.8	5.2	19124	2	US-08-487-826B-13	Sequence 13, Appli
c	33	36.6	5.1	10640	4	US-09-417-485D-5	Sequence 5, Appli
c	34	36.6	5.1	11131	4	US-10-204-708-27	Sequence 27, Appli
c	35	36.6	5.1	51952	3	US-08-947-823-1	Sequence 1, Appli
c	36	36.4	5.1	408	4	US-09-134-001C-1464	Sequence 1464, Ap
c	37	36.4	5.1	1946	4	US-09-886-319A-83	Sequence 83, Appli
c	38	36.4	5.1	3331	3	US-09-042-785A-1	Sequence 1, Appli
c	39	36.4	5.1	161652	4	US-09-497-855A-40	Sequence 40, Appli
c	40	36.2	5.1	6113	4	US-10-204-708-14	Sequence 14, Appli
c	41	36	5.0	6317	4	US-10-204-708-11	Sequence 11, Appli
c	42	36	5.0	11050	4	US-10-204-708-86	Sequence 86, Appli
c	43	36	5.0	50000	4	US-09-146-053-3	Sequence 3, Appli
c	44	35.8	5.0	1634	4	US-09-220-132-111	Sequence 111, App
c	45	35.8	5.0	2570	2	US-09-056-075-2	Sequence 2, Appli

Search completed: May 29, 2004, 11:16:47
Job time : 1280 secs